<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004678" GROUP_ID="MS" ID="072502050509424430" MERGED_FROM="" MODIFIED="2010-04-14 16:41:03 +0200" MODIFIED_BY="Liliana Coco" NOTES="&lt;p&gt;visto che dobbiamo pubblicarla come substantial revision penso che potrebbe essere utilecambiare il &lt;i&gt;titolo come detto&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;marker&quot;&gt;&lt;i&gt;FATTO&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;aggiungere tav&amp;#249;bella summary of findings nel testo&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;marker&quot;&gt;PUOI AGGIUNGERE TU IL LINK?&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Altre piccole modifiche apportate:&lt;/p&gt;&lt;p&gt;1. What's new section: aggiunto nota per modifica titolo&lt;/p&gt;&lt;p&gt;2. Aggiunto referenza RevMan &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-04-14 12:22:07 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.14">
<COVER_SHEET MODIFIED="2010-04-14 12:22:07 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-04-14 10:53:45 +0200" MODIFIED_BY="[Empty name]">Glatiramer acetate for multiple sclerosis</TITLE>
<CONTACT>
<PERSON ID="14862" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Loredana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>La Mantia</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>lamantia@istituto-besta.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neuroscience</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta</ORGANISATION>
<ADDRESS_1>Via Celoria, 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milano</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-02-2394 2348</PHONE_1>
<PHONE_2/>
<FAX_1>+39-02-70638217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-01-26 22:40:44 +0100" MODIFIED_BY="Loredana La Mantia">
<PERSON ID="14862" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Loredana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>La Mantia</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>lamantia@istituto-besta.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neuroscience</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta</ORGANISATION>
<ADDRESS_1>Via Celoria, 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milano</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-02-2394 2348</PHONE_1>
<PHONE_2/>
<FAX_1>+39-02-70638217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14867" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Luca</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Munari</LAST_NAME>
<SUFFIX/>
<POSITION>General Director</POSITION>
<EMAIL_1>luca.munari@sapio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Sapio Life</ORGANISATION>
<ADDRESS_1>Via Silvio Pellico 48</ADDRESS_1>
<ADDRESS_2/>
<CITY>Monza</CITY>
<ZIP>20052</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 - 039 83981</PHONE_1>
<PHONE_2/>
<FAX_1>+39 - 039 2026143</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14863" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roberta</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lovati</LAST_NAME>
<SUFFIX/>
<POSITION>Medico Palliative Care</POSITION>
<EMAIL_1>rob.lovati@tiscali.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>347 1504820</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>U.O. Oncologia</DEPARTMENT>
<ORGANISATION>Ospedale San Paolo</ORGANISATION>
<ADDRESS_1>Di Rudini, 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milano</CITY>
<ZIP>20142</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-347-1504820</PHONE_1>
<PHONE_2>+39-02-81844132</PHONE_2>
<FAX_1>039-02-6101657</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-04-14 11:09:40 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="9" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="1" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-14 12:22:07 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-04-14 12:22:07 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>The review title has been modified from "Therapy with Glatiramer acetate for multiple sclerosis" to "Glatiramer acetate for multiple sclerosis".</P>
<P>Dr. L. La Mantia joined the review team. She updated the review and integrated new data and co-authors comments.</P>
<P>The outcome measures did not change; however a better description of the outcomes has been performed. Furthermore, the type of analysis changed substantially according to the grouping of included patients.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-04-14 11:13:06 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>searches were re-run.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-07 14:06:13 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-07 14:06:13 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-29 10:31:32 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="23" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Searches updated to 31 December 2004</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-08-29 10:29:49 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="19" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Feedback and reply added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-04-14 11:19:58 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-12-20 14:37:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-29 10:06:28 +0200" MODIFIED_BY="Liliana Coco">The use of glatiramer acetate (Copaxone ®) in people with multiple sclerosis</TITLE>
<SUMMARY_BODY MODIFIED="2009-12-20 14:37:21 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2004 , Issue 1 . Art. No.: CD004678. DOI: 10.1002/14651858.CD004678)</P>
<P>Treatment with glatiramer acetate (Copaxone ®) of patients with Relapsing-Remitting (RRMS) and with Progressive Multiple Sclerosis (PMS) seems to have few beneficial effects in  RRMS, while the drug is not effective in PMS patients</P>
<P>Previous studies indicate that glatiramer acetate, a synthetic drug, is effective in animal models of MS, and shows some benefits in MS patients. The objective of this review was to assess the efficacy of glatiramer acetate in RRMS and PMS patients.</P>
<P>Among the pertinent medical literature six studies met the criteria of the methodological quality necessary for their inclusion in this review. 540 RRMS patients and 1049 PMS patients contributed to this analysis. </P>
<P>The data showed no beneficial effects on disease progression in both MS forms, a slight beneficial effect  in the reduction of risk of relapses in RRMS patients and no benefits in PMS patients. Adverse events such as flushing, chest tightness, sweating, palpitations, anxiety and  local injection-site reactions occurred quite frequently, but no major adverse effects were observed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-12-20 17:38:14 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-11-03 11:37:26 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2004 , Issue 1 . Art. No.: CD004678. DOI: 10.1002/14651858.CD004678)</P>
<P>Previous studies have shown that glatiramer acetate (Copaxone ®), a synthetic amino acid polymer is effective in experimental allergic encephalomyelitis (EAE), and improve the outcome of patients with multiple sclerosis (MS).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-03 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>To verify the clinical efficacy of glatiramer acetate in the treatment of MS patients with relapsing remitting (RR) and progressive (P) course. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-11-05 12:01:49 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane MS Group Trials Register (26 March 2009), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 1, 2009), MEDLINE (PubMed) (January 1966 to 26 March 2009), EMBASE (January 1988 to 26 March 2009) and hand searching of symposia reports (1990-2009).<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-01 14:21:59 +0200" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) comparing glatiramer acetate and placebo in patients with definite MS, whatever the administration schedule and disease course, were eligible for this review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-05 12:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>Both patients with RR and P MS were analysed. Study protocols were comparable across trials. No major flaws were found in methodological quality. However, efficacy of blinding should be balanced against side effects, including injection-site reactions.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-12-20 14:33:30 +0100" MODIFIED_BY="[Empty name]">
<P>Among 409 retrieved references, we identified 16 RCTs; six of them, published between 1987 and 2007, met the selection criteria and were included in this review. Five hundred and forty RR patients and 1049 PMS contributed to the analysis. In RR MS, a decrease in the mean EDSS score (-0.33 and -0.45), was found respectively at 2 years and 35 months without any significant effect on sustained disease progression. The reduction of mean number of relapse was evident at 1 year (-0.35 ) 2 years (-0.51 ) and 35 months (-0.64), but significant studies ' heterogeneity was found. The number of hospitalisations and steroid courses were significantly reduced. No benefit was shown in P MS patients. No major toxicity was found. The most common systemic adverse event was a transient and self-limiting patterned reaction of flushing, chest tightness, sweating, palpitations, anxiety. Local injection-site reactions were observed in up to a half of patients treated with glatiramer acetate, thus making a blind assessment of outcomes questionable.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-12-20 17:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>Glatiramer acetate did show a partial efficacy in RR MS in term of relapse -related clinical outcomes, without any significant effect on clinical progression of disease measured as sustained disability. The drug is not effective in progressive MS patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-04-14 11:19:58 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-12-20 14:39:33 +0100" MODIFIED_BY="[Empty name]">
<P>Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with either relapsing/remitting or progressive course. The pathology is characterized by random foci of demyelination and axonal loss throughout the CNS. Despite a better knowledge of these pathologic findings in the last decade, little is known about their underlying etiology.<BR/>Based on experimental data, an autoimmune damage of the myelin sheath has been postulated as a mechanism of CNS inflammation. Susceptible animals inoculated with myelin components are known to develop experimental allergic encephalomyelitis (EAE), which is considered a laboratory model of MS (<LINK REF="REF-Wisniewski-1977" TYPE="REFERENCE">Wisniewski 1977</LINK>). Glatiramer acetate (Copaxone ®) is a synthetic amino acid polymer empirically found to suppress EAE. In animal models, the development of EAE can be prevented by glatiramer acetate administration (<LINK REF="REF-Teitelbaum-1997" TYPE="REFERENCE">Teitelbaum 1997</LINK>), possibly due to a displacement of immune cells targeted at native myelin components. Clinical results consistent with this rationale have also been shown in humans, leading to regulatory authorization of MS treatment from 1997 in the US and 2000 in Europe. Furthermore glatiramer acetate has been recently (June 2009) approved in Italy also for the treatment of clinically isolated syndrome with MRI parameters compatible with MS. Given the expectations raised by this agent and its worldwide use, we believe that updating of this systematic review of all randomised controlled trials (RCTs) evaluating glatiramer acetate (<LINK REF="REF-Munari-2004" TYPE="REFERENCE">Munari 2004</LINK>) needs to be undertaken in order to provide both clinicians and consumers with the most comprehensive information.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-12-20 15:05:15 +0100" MODIFIED_BY="[Empty name]">
<P>This review is aimed at determining clinical efficacy and safety of glatiramer acetate in patients with MS.</P>
<P>The main outcomes of interest were:</P>
<P>(1) Clinical progression of disease in terms of sustained disability</P>
<P>(2) Mean changes in EDSS disability score</P>
<P>(3) Frequency of clinical relapses</P>
<P>(4) Number of patients relapse free</P>
<P>(5) Incidence of any adverse events</P>
<P>(6) Patient's quality of life</P>
<P>Secondary questions to be answered concern:</P>
<P>7) Number of patients treated with steroids and number of steroid courses administered during acute relapses or active disease progression</P>
<P>(8) Impact of treatment on hospital admissions and length of stay, in order to detect potential savings both in terms of healthcare resources and patient's time<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-04-14 11:04:44 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-01-26 16:18:56 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All randomised or quasi-randomised controlled trials (RCTs) comparing glatiramer acetate and placebo in patients with definite MS were eligible for the review. Uncontrolled trials and studies where glatiramer acetate has been compared with interventions other than placebo were not included. Both double-blind and single-blind studies were eligible. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-01-26 16:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>Patients of any age and either gender with definite MS according to Poser criteria (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>), whatever disease severity, were eligible for the review. Any patterns of MS course (relapsing/remitting (RR) relapsing/progressive, secondary progressive or primary progressive (P) have been considered. MS patients receiving cytostatics, immuno modulators or immunosuppressants in the 6 months prior to study enrolment were excluded from the analysis. Therefore, information on patient treatment regimens before entering the trial has been sought.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All therapeutic schedules involving glatiramer acetate administration, whatever the administration route, dosage, treatment duration and the interval between symptom onset and randomisation were considered as test treatment. Courses of steroids were permitted, provided they were administered without any restriction in both arms.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-01-13 11:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>We sought the following measures in both treatment groups at 12 and 24 months and at the end of the scheduled follow-up period:</B>
<BR/>Patients who progressed. Whenever unspecified, progression has been defined as a persistent worsening of at least one point in EDSS (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>), recorded out of relapse and confirmed by a follow-up assessment at six months (<LINK REF="REF-Rio-2002" TYPE="REFERENCE">Rio 2002</LINK>). However, other definitions of progression given in the original paper could be accepted, including a persistent half-point increase starting from EDSS score &#8805; 5.5 (<LINK REF="REF-Rio-2006" TYPE="REFERENCE">Rio 2006</LINK>).<BR/>Mean changes in EDSS disability score<BR/>We considered different relapse-related clinical outcomes and in particular : Frequency of clinical relapses, number of patients relapse free and number of patients relapse free over time.</P>
<P>Secondary questions to be answered concern:<BR/>Number of patients treated with steroids and number of steroid courses administered during acute relapses or active disease progression and impact of treatment on hospital admissions and length of stay, in order to detect potential savings both in terms of healthcare resources and patient's time.<BR/>
<BR/>
</P>
<P>
<B>Safety outcomes were assessed among primary endpoints by unique measures cumulating all events occurred throughout the trial</B>:<BR/>Number of both local and systemic side effects.<BR/>Number of patients with severe side effects. If not otherwise specified, side effects have been defined as severe when leading to one of the following: death, hospitalisation, treatment discontinuation.<BR/>
<B>
<BR/>
</B>
</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-12-20 15:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>A systematic search without language restrictions was conducted using the optimally sensitive strategy developed for the Cochrane Collaboration to identify all relevant published and unpublished randomised controlled trials (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>).</P>
<P>For additional information about the Group's search strategy please see: <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Cochrane Multiple Sclerosis Group</A>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-11-02 11:49:45 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases:</P>
<OL>
<LI>The Cochrane Multiple Sclerosis Group Trials Register (26 March 2009)</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) "The Cochrane Library" (issue 1, 2009) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>MEDLINE (PubMed) (January 1966 to 26 March 2009) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>EMBASE (EMBASE.com) (1974 to 26 March 2009) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-10-01 21:34:11 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Handsearched references quoted in the identified trials</LI>
<LI>Handsearched symposia reports (1990-2009) from the most important neurological associations and MS Societies in Europe and America;</LI>
<LI>Contacted researchers who were participating in trials on GA.</LI>
</OL>
<P>Contacts with the owner pharmaceutical company (Teva Pharmaceutical, Ltd.) were attempted without reply. So, we established reliable contacts with researchers involved in GA development.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-04-14 11:04:44 +0200" MODIFIED_BY="[Empty name]">
<P>DATA EXTRACTION<BR/>Selection of eligible studies and data extraction have been carried out independently by three reviewers (LM, LLM, RL). Results were then compared in order to rule out any misunderstandings, mistakes or biases possibly arising from data evaluation. Details on treatment administration schedule, patient enrolment criteria, diagnostic criteria, randomisation methods, blinding, outcome analysis, follow-up length, dropouts, side effects were also recorded for each study, in order to evaluate quality profiles (see Methodological quality). All data were entered in a collection form. Disagreements were resolved by discussion amongst reviewers.<BR/>Trialists were asked to provide further details on study characteristics if they were unclear in the article.</P>
<P>TRIAL QUALITY ASSESSMENT</P>
<P>The methodological quality of each trial was assessed independently by reviewers. We used the recommended methods outlined in the <I>Cochrane Reviewers Handbook </I>version 5.0.0 (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).<BR/>All studies were given a quality score ranging from 0 to 5 (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), based on the following criteria: randomisation, allocation concealment, blinding, decisions about dropouts and withdrawals. Relevant information was collected using a data extraction form developed by the Multiple Sclerosis Cochrane Review Group.<BR/>Randomisation has been defined as either telephone calls to a randomisation centre, reference to computer-generated random lists or tables of random numbers. Quasi-randomised trials without properly concealed allocation (e.g.: patient alternation, open random list, date of birth, day of the week or hospital admission number) have been included in the review.</P>
<P>Allocation concealment and blinding have been scored in the risk of bias tables for each included study. Disagreements were resolved by discussion among the authors in order to achieve a unique score for each considered item. In case of significant differences between treatment and placebo, the effect of blinding could be tested in sensitivity analysis, since knowledge of treatment allocation may affect the assessment of study endpoints.<BR/>Trial quality scores are listed in the additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>STATISTICAL ANALYSIS<BR/>Data have been analysed according to an intention-to-treat approach. Relative risks, risk difference and their 95% confidence intervals (CI) have been calculated for binary outcomes. Continuous outcomes have been evaluated as weighted mean differences in treatment effects and their standard deviation (SD).<BR/>The weighted treatment effect was calculated across trials for each outcome. Combined results were expressed as weighted estimates of relative risks with their 95% CI when binary variables were considered. Continuous outcomes were combined using weighted mean differences and their 95% CI.<BR/>Basically, data were analysed in a fixed-effect model (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). Homogeneity across trials have been tested in a chi square test with alpha=0.10. When significant heterogeneity was found, results were checked in a random-effects model (<LINK REF="REF-Brocke-1996" TYPE="REFERENCE">Brocke 1996</LINK>).<BR/>Characteristics of trials have been listed in the corresponding "Characteristics of Included/excluded studies". All results have been organised and processed by the Review Manager 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) developed by the Cochrane Collaboration.<BR/>The effects of potential sources of heterogeneity have been explored by subgroup analysis where appropriate (see results).<BR/>Sensitivity analysis on trial quality and missing data was not needed.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-04-14 11:15:08 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-04-14 11:15:08 +0200" MODIFIED_BY="[Empty name]">
<P>Out of 409 references identified by the search strategy up to 26 March 2009, 133 abstracts were provisionally selected to be read as full published papers. Ninety three papers were then excluded for the following reasons: 53 were uncontrolled open-label studies (<LINK REF="STD-Abramsky-1977" TYPE="STUDY">Abramsky 1977</LINK>; <LINK REF="STD-Baumhefner-1988" TYPE="STUDY">Baumhefner 1988</LINK>; <LINK REF="STD-Boiko-2006" TYPE="STUDY">Boiko 2006</LINK>; <LINK REF="STD-Bornstein-1982" TYPE="STUDY">Bornstein 1982</LINK>;<LINK REF="STD-Brochet-2008" TYPE="STUDY">Brochet 2008</LINK>;<LINK REF="STD-Caon-2006" TYPE="STUDY">Caon 2006</LINK>; <LINK REF="STD-Capobianco-2008" TYPE="STUDY">Capobianco 2008</LINK>; <LINK REF="STD-Carra-2008" TYPE="STUDY">Carra 2008</LINK>; <LINK REF="STD-Daugherty-2005" TYPE="STUDY">Daugherty 2005</LINK>; <LINK REF="STD-De-Seze-2000" TYPE="STUDY">De Seze 2000;</LINK> <LINK REF="STD-De-Stefano-2008" TYPE="STUDY">De Stefano 2008</LINK>; <LINK REF="STD-De-Stefano-2009" TYPE="STUDY">De Stefano 2009</LINK>; <LINK REF="STD-Debouverie-2007" TYPE="STUDY">Debouverie 2007</LINK> ; <LINK REF="STD-Duda-2000" TYPE="STUDY">Duda 2000</LINK>; <LINK REF="STD-Flechter-2002b" TYPE="STUDY">Flechter 2002b</LINK>;<LINK REF="STD-Ford-2006" TYPE="STUDY">Ford 2006</LINK>; <LINK REF="STD-Fusco-2001" TYPE="STUDY">Fusco 2001</LINK>; <LINK REF="STD-Gajofatto-2009" TYPE="STUDY">Gajofatto 2009</LINK> ;<LINK REF="STD-Garcia_x002d_Barragan-2009" TYPE="STUDY">Garcia-Barragan 2009</LINK>; <LINK REF="STD-Ghezzi-2005" TYPE="STUDY">Ghezzi 2005</LINK>; <LINK REF="STD-Ghezzi--b-2005" TYPE="STUDY">Ghezzi b 2005</LINK>; <LINK REF="STD-Haas-2005" TYPE="STUDY">Haas 2005</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Johnson-2003" TYPE="STUDY">Johnson 2003</LINK>; <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>; <LINK REF="STD-Khan-2001" TYPE="STUDY">Khan 2001</LINK>; <LINK REF="STD-Kott-1997" TYPE="STUDY">Kott 1997;</LINK> <LINK REF="STD-Lage-2006" TYPE="STUDY">Lage 2006</LINK> ; <LINK REF="STD-Le-Page-2008" TYPE="STUDY">Le Page 2008</LINK>; <LINK REF="STD-Mancardi-1998" TYPE="STUDY">Mancardi 1998</LINK>; <LINK REF="STD-Meiner-1997" TYPE="STUDY">Meiner 1997</LINK>; <LINK REF="STD-Milanese-2005" TYPE="STUDY">Milanese 2005</LINK> ; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Miller-2006" TYPE="STUDY">Miller 2006</LINK>;<LINK REF="STD-Miller-2008" TYPE="STUDY">Miller 2008</LINK>; <LINK REF="STD-Ollendorf-2008" TYPE="STUDY">Ollendorf 2008</LINK>; <LINK REF="STD-Orlova-2005" TYPE="STUDY">Orlova 2005</LINK>; ;<LINK REF="STD-Ramtahal-2006" TYPE="STUDY">Ramtahal 2006</LINK>; <LINK REF="STD-Rio-2005" TYPE="STUDY">Rio 2005</LINK> ; <LINK REF="STD-Rovaris-2007" TYPE="STUDY">Rovaris 2007</LINK> ;<LINK REF="STD-Schwid-2007" TYPE="STUDY">Schwid 2007</LINK> ; <LINK REF="STD-Sindic-2005" TYPE="STUDY">Sindic 2005</LINK>; <LINK REF="STD-Tilbery-2006" TYPE="STUDY">Tilbery 2006</LINK>; <LINK REF="STD-Torkildsen-2007" TYPE="STUDY">Torkildsen 2007</LINK>;<LINK REF="STD-Twork-2007" TYPE="STUDY">Twork 2007</LINK> ; <LINK REF="STD-Valenzuela-2007" TYPE="STUDY">Valenzuela 2007</LINK>; <LINK REF="STD-Vallittu-2005" TYPE="STUDY">Vallittu 2005</LINK>; <LINK REF="STD-Weder-2005" TYPE="STUDY">Weder 2005</LINK>; <LINK REF="STD-Wolinsky-2001" TYPE="STUDY">Wolinsky 2001</LINK>;<LINK REF="STD-Ytterberg-2007" TYPE="STUDY">Ytterberg 2007</LINK> ;<LINK REF="STD-Zavalishin-2005" TYPE="STUDY">Zavalishin 2005</LINK>; <LINK REF="STD-Ziemssen-2008" TYPE="STUDY">Ziemssen 2008</LINK>; <LINK REF="STD-Zwibel-2006" TYPE="STUDY">Zwibel 2006</LINK>) .</P>
<P>Five studies were controlled not randomised studies evaluating the efficacy of GA and other immunomodulating agents without placebo group (<LINK REF="STD-Castelli_x002d_Haley-2008" TYPE="STUDY">Castelli-Haley 2008</LINK>;<LINK REF="STD-Deen-2008" TYPE="STUDY">Deen 2008</LINK>; <LINK REF="STD-Flechter-2002a" TYPE="STUDY">Flechter 2002a</LINK>;<LINK REF="STD-Khan-2005" TYPE="STUDY">Khan 2005</LINK>; <LINK REF="STD-Zavalishin-2006" TYPE="STUDY">Zavalishin 2006</LINK>) , 7 studies restricted the analysis to MRI parameters (<LINK REF="STD-Cohen-1995" TYPE="STUDY">Cohen 1995</LINK>; <LINK REF="STD-Mesaros_x002c_-2008" TYPE="STUDY">Mesaros, 2008</LINK>; <LINK REF="STD-Rovaris-2005" TYPE="STUDY">Rovaris 2005</LINK>; <LINK REF="STD-Shipova-2009" TYPE="STUDY">Shipova 2009</LINK>; <LINK REF="STD-Sormani-2002" TYPE="STUDY">Sormani 2002</LINK>; <LINK REF="STD-Sormani-2005" TYPE="STUDY">Sormani 2005</LINK>; <LINK REF="STD-Sormani-2007" TYPE="STUDY">Sormani 2007</LINK>) 7 studies reported on experimental investigations where only laboratory endpoints have been assessed (lymphocyte activity, cytokine outburst, uric acid increase) or clinical immunological studies ( <LINK REF="STD-Blanco-2006" TYPE="STUDY">Blanco 2006</LINK>; <LINK REF="STD-Brenner-2001" TYPE="STUDY">Brenner 2001</LINK>; <LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK>; <LINK REF="STD-Constantinescu-2000" TYPE="STUDY">Constantinescu 2000</LINK>; <LINK REF="STD-Farina-2001" TYPE="STUDY">Farina 2001</LINK>; <LINK REF="STD-Karandikar-2002" TYPE="STUDY">Karandikar 2002</LINK>; <LINK REF="STD-Qin-2000" TYPE="STUDY">Qin 2000</LINK>), 21 studies aimed to evaluate adverse events during treatment with GA ( <LINK REF="STD-Achiron-2005" TYPE="STUDY">Achiron 2005</LINK>; <LINK REF="STD-Ball-2008" TYPE="STUDY">Ball 2008</LINK> ; <LINK REF="STD-Bosca-2006" TYPE="STUDY">Bosca 2006</LINK>; <LINK REF="STD-Charach-2008" TYPE="STUDY">Charach 2008</LINK>; <LINK REF="STD-Cicek-2008" TYPE="STUDY">Cicek 2008</LINK>; <LINK REF="STD-Feigin-2005" TYPE="STUDY">Feigin 2005</LINK>; <LINK REF="STD-Fiore-2005" TYPE="STUDY">Fiore 2005</LINK> ; <LINK REF="STD-Harde-2007" TYPE="STUDY">Harde 2007</LINK>; <LINK REF="STD-khan-2008" TYPE="STUDY">khan 2008</LINK> ; <LINK REF="STD-La-Mantia-2006" TYPE="STUDY">La Mantia 2006</LINK>; <LINK REF="STD-Madray-2008" TYPE="STUDY">Madray 2008</LINK>; ; <LINK REF="STD-Neumann-2007" TYPE="STUDY">Neumann 2007</LINK>; <LINK REF="STD-Nolden-2005" TYPE="STUDY">Nolden 2005</LINK>; <LINK REF="STD-Patten-2008" TYPE="STUDY">Patten 2008</LINK>;<LINK REF="STD-P_x00f6_llmann-2006" TYPE="STUDY">Pöllmann 2006</LINK>; <LINK REF="STD-Rauschka-2005" TYPE="STUDY">Rauschka 2005</LINK>; <LINK REF="STD-Sidoti-2007" TYPE="STUDY">Sidoti 2007</LINK>;<LINK REF="STD-Soares-2006" TYPE="STUDY">Soares 2006</LINK>; <LINK REF="STD-Then_x002c_-Bergh-F-2006" TYPE="STUDY">Then, Bergh F 2006</LINK>; <LINK REF="STD-Thouvenot-2007" TYPE="STUDY">Thouvenot 2007</LINK>; <LINK REF="STD-Tremlett-2007" TYPE="STUDY">Tremlett 2007</LINK>) (See table of excluded studies).</P>
<P>The remaining papers were related to 16 RCTs, nine RCTs were excluded because comparative trials evaluating the efficacy of two dosages of GA (<LINK REF="STD-Cohen-2007" TYPE="STUDY">Cohen 2007</LINK>; <LINK REF="STD-Wynn-2008" TYPE="STUDY">Wynn 2008</LINK>), of GA versus IFN beta (<LINK REF="STD-Cadavid-2009" TYPE="STUDY">Cadavid 2009</LINK>;<LINK REF="STD-Mikol-2008" TYPE="STUDY">Mikol 2008</LINK> ) of natalizumab versus placebo in Ga -treated MS patients (<LINK REF="STD-Goodman-2009" TYPE="STUDY">Goodman 2009</LINK> ) of GA after induction with mitoxantrone vs GA alone (<LINK REF="STD-Vollmer-2008" TYPE="STUDY">Vollmer 2008</LINK>;<LINK REF="STD-Arnold-2008" TYPE="STUDY">Arnold 2008</LINK>) or cognitive function in GA versus placebo ( <LINK REF="STD-Weinstein-1999" TYPE="STUDY">Weinstein 1999</LINK>) or treatment of local reaction (<LINK REF="STD-Jolly-2008" TYPE="STUDY">Jolly 2008</LINK> ). One study was excluded because evaluating the efficacy of GA in isolated central nervous system syndrome ( <LINK REF="STD-Comi-2008" TYPE="STUDY">Comi 2008</LINK>).</P>
<P>Six RCTs contributing to this review (29 related references) published between 1987 and 2007 (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>:<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ;<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>). These studies account for a total of 3233 patients, 2043 of whom allocated to glatiramer acetate and 1190 to placebo. Four studies enrolled patients with relapsing-remitting (RR) disease (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>; <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>;). Two RCTs investigated the effect of glatiramer acetate in progressive MS (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK> <LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>). Therapeutic schedules were homogeneous, except for <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> study evaluating oral administration of GA. This trial was separately analyzed for concerns about the comparability of parenteral and oral administration . Therefore, the following treatments have been compared with placebo:</P>
<UL>
<LI>glatiramer acetate: 20 mg subcutaneously, self-administered daily in RR MS</LI>
<LI>glatiramer acetate 50-5 mg oral-administered daily in RRMS</LI>
<LI>glatiramer acetate: 30 mg-20 mg subcutaneously, self-administered daily in P MS</LI>
</UL>
<P>The treatment has been given for 9 (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), 14 (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ) 24 (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>) or 35 months (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>). and 36 months (<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>). The characteristics of the studies are reported in the corresponding tables.</P>
<P>All trials on RR MS enrolled patients with definite disease (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>). Bornstein et al. (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>) randomised patients within an age range of 20 to 35 years, with at least two exacerbations in the two years before admission, provided they were not severely disabled (EDSS score below 6) and/or emotionally unstable. Fifty-eight percent of study population were female and 64% of initially screened patients were excluded due to any of the following: age, low frequency of exacerbations, lack of documentation, impaired psychological profile, transition to CP MS, distance from the clinic or pregnancy.<BR/>The US phase III pivotal trial (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>) was a multicentre study involving 11 centres in the US. Eligible patients had an EDSS &#8804; 5 and at least two documented relapses in the two years prior to entry, the last one occurring at least one year before randomisation; they should also be neurologically stable and free from corticosteroid therapy for at least 30 days prior to entry. Patients could be enrolled within a larger age range (18 to 45) and the final proportion of female subjects was 73%. Only 12% of candidate participants were excluded based on the following criteria: treatment with glatiramer acetate or previous immunosuppression with cytotoxic therapy or lymphoid irradiation, pregnancy or lactation, diabetes mellitus, positive HIV/HTLV-1 serology, Lyme disease, need of aspirin or chronic non-steroidal anti-inflammatory drugs throughout the trial, unwillingness to undergo adequate contraception. Only EDSS modifying attacks confirmed by current neurological examination were accepted as relapses. Out of 215 patients who completed the first 24-month follow-up, 203 entered an additional 11-month treatment schedule (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>), reproducing the same trial design. The investigators also carried out a further open-label follow-up up to six years from randomisation in 208 patients (<LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>;<LINK REF="STD-Johnson-2003" TYPE="STUDY">Johnson 2003</LINK>), to 8 years in 142 patients (<LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK> ) to 10 years in 108 patients (<LINK REF="STD-Ford-2006" TYPE="STUDY">Ford 2006</LINK>) from the original cohort of 251, not included in this review.<BR/>The European-Canadian MRI study (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>) applied the following inclusion criteria: patients aged 18 to 50 with an EDSS &#8804; 5 with MS from at least one year. One documented relapse in the preceding two years was deemed sufficient to enter the study, but at least 1 enhancing lesion was essential in the screening brain MRI. Moreover, all randomised patients were clinically relapse-free and steroids-free in the 30 days before entry. A total of 29 centres participated in the study and 51% of screened patients were excluded due to any of the following: previous use of glatiramer acetate or oral myelin, prior lymphoid irradiation, use of immunosuppressant or cytotoxic agents in the past two years, use of azathioprine and/or other immunosuppressant including steroids during the previous six months, concomitant therapy with an experimental drug for either MS or another disease, serious intercurrent systemic or psychiatric illnesses; unwillingness to practice reliable contraception during study and known hypersensitivity to gadolinium, unavailability to repeat MRI studies. We excluded from the review the 9-month open-label extension phase of this trial.</P>
<P>Flippi' study (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) was separately evaluated. This study assessed whether two doses of glatiramer acetate given orally could improve clinical and MRI measures of inflammation and neurodegeneration in a large cohort of patients with relapsing-remitting multiple sclerosis. One thousand nine hundred and twelve patients with relapsing-remitting multiple sclerosis were screened and 1651 were randomised to receive 50 mg or 5 mg of glatiramer acetate or placebo by daily oral administration over 14 months. The intention-to-treat cohort consisted of 1644 patients who took at least one dose of study medication (50 mg glatiramer acetate [n=543], 5 mg glatiramer acetate [n=553], placebo [n=548]). After baseline investigation, clinical assessments were done every 2 months and MRI was obtained for all patients at baseline and at study exit.<BR/>
</P>
<P>The main clinical data of the patients are reported in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Briefliy RR showed a disease duration ranging from 5.5 to 8.1 years, low disability and active clinical disease. Patients enrolled in the European-Canadian MRI study may represent a less severe subset, since they were eligible after a single relapse in the two previous years; however in this study an active MRI scan was needed. Patients enrolled had to be free of any steroid treatment for at least 30 days (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>; <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) and clinically stable for at least 30 days (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>). Minimum time elapsed from the last relapse was not specified in one study (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>).</P>
<P>The study of <LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK> randomised patients between the age of 20 and 60, with a chronic-progressive course for at least 18 months, less than two exacerbations in the previous 24 months, disability 2-6.5 on EDSS, emotional stability and a favourable psychosocial profile. These criteria were assessed in a pre-trial observation period lasting no more than 15 months and led to exclude 47% of candidate participants. The inclusion criteria may suggest that patients were affected by secondary progressive or progressive relapsing course.The primary outcome was confirmed progression (worsening of 1 EDSS or 1.5 according to basal EDSS ( 5 or less) maintained at 3 months.</P>
<P>The <LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK> study included primary progressive multiple sclerosis randomized to GA or placebo (PBO) in a 3-year, double-blind trial. 37 patients out of 943 have been confirmed relapses during the follow-up, suggesting that a small proportion of patients exhibited the progressive relapsing phenotype . The primary end point was an intention-to-treat analysis of time to 1- (entry EDSS 3.0-5.0) or 0.5-point expanded disability status scale change (entry EDSS 5.5-6.5) sustained for 3 months. The trial was stopped after an interim analysis by an independent data safety monitoring board indicated no discernible treatment effect on the primary outcome.</P>
<P>The main clinical data of the Progressive patients are reported in the <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.; the patients were more disable than RR MS and had a longer disease duration.</P>
<P>CLINICAL OUTCOMES</P>
<P>The studies on RR MS reported as primary outcome measures:</P>
<P>Proportion of relapse-free patients at the end of follow-up (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>), mean number of relapses (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>), total number of enhancing lesions on T1-weighted MRI images (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), the total number of confirmed relapses (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>).</P>
<P>Studies on RR MS also evaluated the following secondary (and tertiary) endpoints: time to progression (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>), proportion of patients with sustained disease progression (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>),change in EDSS scores from baseline (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) and area under curve for the EDSS change (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) time to walk and ambulation index (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) relapse rate (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), number of relapses (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), proportion of relapse-free patients (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>,<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ), time to first relapse after randomisation ( <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>,<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ) the proportion of patients with two or more relapses (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>, ), steroid courses (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK> ;<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ) and relapse-related hospitalizations (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>,<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ) and other MRI measures (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>: <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>). MRI data of <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>'s study were reported in 135 out of the 251 patients of the original cohort in the open -label extension trial (<LINK REF="STD-Wolinsky-2001" TYPE="STUDY">Wolinsky 2001</LINK>).</P>
<P>Progression was defined in all studies as an increase of at least 1 point EDSS maintained for at least 3 months (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>). It is noteworthy that the review protocol was more conservative, requiring at least 6 months of sustained 1-point EDSS worsening to be classified as progression, even if other definitions could be accepted.</P>
<P>As a separate endpoint from progression, 2 trials analysed the proportion of patients worsened by at least 1 point in disability score at the end of follow-up as compared to baseline (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>). It assumed that this endpoint does not take into account if a sustained increase in EDSS score has occurred, and it is open to misinterpretations as to the final patient outcome. Therefore, we have chosen not to analyse clinical worsening as reported by these studies in order to avoid misleading results when inconsistent with those obtained in disease progression (see Discussion). Consistently, clinical improvement based on a &#8805;1 point decrease in EDSS score versus baseline was not analysed.</P>
<P>Relapse was defined as the appearance or reappearance of one or more neurologic symptoms, with signs persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurologic state of at least 30 days (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>;<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ). Another trial protocol required that patient symptoms were associated with changes in the neurologic exam involving an increase of at least 1 point in any of the 8 Kurtzke functional groups. Sensory symptoms alone were not considered (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>).The relapse was confirmed when the symptoms were accompanied by objectives changes corresponding to an increase of 0.5 EDSS or 1 grade in the two or more functional systems (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>; <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>),</P>
<P>The studies on Progressive MS reported as primary outcome measures:</P>
<P>time to sustained confirmed at 3 months, of 1 point of EDSS increase (according to baseline EDSS of 5.0 or more) (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>) , of 1.5 EDSS increase ( Baseline EDSS less than 5) (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>) or 1 (basal EDSS 3-5) and 0.5 (basal EDSS 5.5 or more) ( <LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>).</P>
<P>as secondary outcome measures unconfirmed progression and progression of 0.5 EDSS units (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>) and proportion of progression free, changes from baseline in mean EDSS score and mean MSFC scores and MRI measures (<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>)</P>
<P>SIDE EFFECTS AND ADVERSE EVENTS</P>
<P>The number of patients experiencing side effects of treatment have been counted, by event, in all studies. However, information on how many patients reported at least one adverse event whatever was unavailable, so that the overall incidence of side effects could not be calculated.<BR/>The number of patients who dropped out because of adverse effects could be extracted from studies (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>: <LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>).</P>
<P>SECONDARY ENDPOINTS</P>
<P>Two studies have compared the number of hospitalisations observed at the end of follow-up between glatiramer acetate and placebo arms (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>). Number of relapses requiring hospitalisation was also evaluated in Filippi's study (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) but that data were not shown. Data on the number of steroid courses administered were also available from two studies (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>).</P>
<P>MRI PARAMETERS</P>
<P>One study (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>) evaluated the total number of enhancing lesions on MRI as the primary endpoint, clinical outcomes being analysed as tertiary endpoints. Secondary outcomes of this trial were: total volume of enhancing lesions, number of new enhancing lesions, number of new lesions on T2-weighted images, percentage change of lesion volume on T2-weighted images, change in the volume of hypointense lesions on T1-weighted images. MRI parameters were also analysed in secondary reports from the US phase III pivotal study, both for a small subset of the main trial (<LINK REF="REF-Ge-2000" TYPE="REFERENCE">Ge 2000</LINK>) and the open-label extension phase (<LINK REF="STD-Wolinsky-2001" TYPE="STUDY">Wolinsky 2001</LINK>).</P>
<P>CONCOMITANT MEDICATION</P>
<P>In two studies, standard steroid treatment could be administered during relapses, without restrictions (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>). Moreover, symptomatic medications (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>) or conventional therapy received at the time of randomisation (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>) could be maintained throughout the study. A standard treatment schedule for relapses was specified in one trial protocol as 1.0 g i.v. methylprednisolone for three consecutive days (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>). Limitations to the use of steroids were introduced in the CP study (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>), where the maximum dose should not exceed 100 mg prednisone or 80 UI ACTH daily during exacerbations, lasting no more than four weeks.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-04-14 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<P>(summary data are reported in <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK> and <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>)</P>
<P>RANDOMISATION</P>
<P>Method of randomization are reported in risk of bias tables (see tables of characteristics of included studies).Allocation concealment was adequate in four studies <LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>; <LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006 </LINK>) and not reported in one study (<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>) In another study (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>) patients were randomised within matched pairs, but the method to obtain treatment allocation was not clearly specified. Allocation concealment was therefore defined as "unclear" for this report.</P>
<P>BLINDING</P>
<P>All trials were double-blind in design. However, the occurrence of peculiar side effects of glatiramer acetate (e.g.: injection site and skin reactions) casts doubts on the possibility to ensure a reliable masking. In the attempt to reduce this flaw, all study protocols introduced a separate evaluation by two independent physicians: an examining neurologist was responsible for the scheduled monitoring of clinical endpoints, while a treating physician was in charge of managing side effects and concomitant therapy. The latter physician could be either aware (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>;<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ;<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>) or unaware (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>) of patient allocation. In another study, blinding of physicians was not formally assessed because clinical endpoints were only considered as tertiary outcomes (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>).<BR/>Independently of investigators' accuracy, it can be assumed that all trials failed to carry out a fully blind assessment. In one study claimed to be double blind (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>), both patients and physicians correctly identified 70 to 80% of treatment allocations. Surprisingly, however, investigators stated that "the ability to guess treatment correctly was influenced by the effect of treatment rather than by side effects".</P>
<P>WITHDRAWALS AND LOST TO FOLLOW-UP</P>
<P>Bornstein et al. (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>) report that two patients out of 25 allocated to placebo discontinued the study and were excluded from the analysis because of unreliable data due to an altered psychological profile. This was considered as a violation of the intention-to-treat analysis. Therefore, we had to count 23 participants in the placebo arm when data were extracted from either percentages or means in the original paper. Data from other five patients who dropped out were analysed, two in the placebo arm and three allocated to glatiramer acetate. One exacerbation and two adverse events were counted in this group.<BR/>The US pivotal trial (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>) counted 19 withdrawals in glatiramer acetate-treated patients and 17 among those taking placebo. Causes of discontinuation were not reported in 10 glatiramer acetate-allocated patients and 14 controls, representing 9.6% of the randomised sample altogether. Out of 215 patients who completed the first 24-month follow-up, 12 refused to enter the 11-month extension having opted to receive the newly emerging beta-interferon therapy. The two-year clinical profiles exhibited by these patients and those enrolled in the extension trial were comparable. A further nine subjects dropped out at the end of the 35-month follow-up (three in the treatment arm, seven allocated to placebo). All data related to this group were included in the analysis, although causes of dropout are not reported in detail.</P>
<P>The European/Canadian trial (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>) had 14 dropouts, equally balanced between treatment and placebo. All of them where included in the analysis.</P>
<P>The oral study (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>) had 14,12,13% of withdrawn in the three experimental groups.<BR/>The CP MS study also reported a balanced withdrawal pattern (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>), with 10 glatiramer acetate treated patients and 10 controls discontinuing medication. Early withdrawals were all included in the analysis: 17 were censored at the time of discontinuation, the other 3 (glatiramer acetate=2, placebo=1) being counted as confirmed progression.</P>
<P>In the <LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK> study 188/627 GA and 98/316 Placebo treated patients withdrew for various reasons before sponsor decision for trial termination. At the end of follow-up only 114/621 (GA) and 46/314 (P) were available for the analysis of the main outcome (See Fig 2 of the paper). Four GA and 7 death Placebo -treated were also reported.<BR/>
<BR/>VALIDITY SCORE</P>
<P>The Jadad score was calculated as a measure of internal validity.</P>
<P>The Jadad score is reported in the additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). One study was given three because of unclear allocation concealment and insufficient details on withdrawn patients and unsuccessful blinding (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>).One study was given three because of unclear allocation concealment and insufficient details on blindness (<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>) The others studies obtained a full score.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-03-05 17:02:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>
</P>
<P>
<B>The efficacy of GA versus placebo was evaluated separately in RR and Progressive MS patients</B>
</P>
<P>A total of 3233 patients, 2184 affected by RR (1365 actively and 819 placebo treated) and 1049 by Progressive MS (678 actively and 371 placebo treated) were included in these trials, although only 540 RR patients and 1049 PMS contributed to the analysis of treatment efficacy.</P>
<P>
<B>Relapsing Remitting MS </B>
</P>
<P>PATIENTS WHO PROGRESSED</P>
<P>Information about progression of disability was available from two trials and 226 patients (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>).The risk of progression was not significantly modified by the therapy at 2 years : 0.75 (95% CI [0.51, 1.12] p=0.16) and at 35 months 0.81 (95% CI [0.50 to 1.29] (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>CHANGE IN DISABILITY SCORE</P>
<P>Mean changes in EDSS disability score were calculated in two trials (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>). As different follow-up durations are available from the US phase III trial, both 24- and 35-month data are shown although results are not pooled. A slight decrease in EDSS score favouring glatiramer acetate is observed at two years (WMD= -0.33, 95% CI [-0.58 to -0.08], p = 0.009) and at 35 months (WMD= -0.45, 95% [-0.77 to -0.13], p = 0.006) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>PATIENTS RELAPSE-FREE</P>
<P>This information was available in three studies and 255 subjects with RR MS, evaluated at different follow-up lengths (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>). Results have been split into three time windows: within 1 year (which includes the 9-month assessment reported in the European/Canadian study), at 2 years and at 35 months. Relative risks of experiencing no exacerbation were, respectively: 1.28 (95% CI[1.02, 1.62] p= 0.03) within 1 year of treatment, and 1.39 (95%C I[0.99, 1.94], p=0-06 at 2 years, and 1.33 (95% CI [0.86, 2.06] at 35 months ( <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Since the same study appears in more than one stratum (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>), no pooled analysis is provided for this outcome. Significant heterogeneity was found between Bornstein's pilot trial and the European/Canadian study (p=0.03), possibly related to different trial duration. Then we tested pooled relative risk of relapse within 1 year of randomisation in a random-effect model, without any significant difference between glatiramer acetate and placebo: relative risk = 0.64 (95% CI [0.31 to 1.34], p= 0.2).<BR/>
<BR/>MEAN NUMBER OF RELAPSES</P>
<P>A significant reduction was found at 1 year (-0.35) at 2 years (-0.51) and at 35 months (-0.64). However a significant heterogeneity was found between the studies( <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>RELAPSE-FREE SURVIVAL</P>
<P>Median time to first relapse was analysed in one study (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>), with a median time of 287 days in patients treated with glatiramer acetate and 198 days in controls (Weibull regression model, p =0.097). Our elaboration on individual patient data extracted from the pilot trial paper (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>) point to a median of 5 months (95% CI [2 to 8]) in the placebo arm, while the median of glatiramer acetate-treated group could not be calculated as more than 50% of those subjects were censored without relapse at 24 months (log-rank chi-square = 6.68, p = 0.0098). These results could not be combined.</P>
<P>ORAL TREAMENT WITH GA</P>
<P>This treatment was considered only by one study (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK> ): the available data did not allowed a meta-analysis according to the predefined protocol.</P>
<P>The cumulative number of confirmed relapses did not differ between the two active treatment groups and the placebo group. Relative to placebo, the rate ratio for the 50 mg glatiramer acetate treated group was 0.92 (95% CI 0.77-1.08, p=0.30) and for the 5 mg glatiramer acetate treated group was 0.98 (0.83-1.15, p=0.76). No drug effect was seen for any of the secondary and tertiary endpoints.</P>
<P>
<B>Progressive MS </B>
</P>
<P>PATIENTS WHO PROGRESSED</P>
<P>This information was available in two studies (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>;<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>) including 832 patients.</P>
<P>Risk of progression was not reduced by GA at 1 year (0.88 (95% CI 0.60,1,27) at 2 years ( 0.84 ( 0.60,1.19) and 3 years 0.75 (0.38,1.50) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).The data must be considered with caution since they were obtained from the survival curve, because not clearly reported in the paper. </P>
<P>CHANGE IN DISABILITY SCORE</P>
<P>This information was available only from one study (<LINK REF="STD-Wolinsky-2007" TYPE="STUDY">Wolinsky 2007</LINK>) including 943 cases.</P>
<P>Mean EDSS scores increased from baseline by 0.61+/-1.13 in the placebo group and by 0.58+/-1.00 point in the GA group (not statistically different) (data unshown).</P>
<P>CHANGES IN QUALITY OF LIFE SCORES</P>
<P>No study planned to analyse patient quality of life as an outcome measure.</P>
<P>ADVERSE EFFECTS</P>
<P>All trials evaluated adverse events, accounting for 407 to 646 patients. Two studies (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>) mainly focused on injection-site changes and patterned transient systemic reactions, while the other two (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>) reported a more analytical list of all observed side effects. Patterned reactions were most commonly reported, consisting of a transient self-limiting combination of: flushing, chest tightness, sweating, palpitations, anxiety. These symptoms unpredictably occurred within minutes of injection and spontaneously resolved before 30 minutes. Patterned reactions were more often observed in glatiramer acetate treated patients, with a relative risk of 3.27 (95% CI[2.07, 5.16]p &lt;0.00001]). Other systemic side effects significantly related to glatiramer acetate administration were: palpitations (relative risk = 3.58 [1.16, 11.06], p =0.03)., dyspnoea 3.58 [1.16, 11.06] p 0 0.005. The incidence of headache, anxiety, faintness, drowsiness, cramps, joint pain, appetite loss, constipation, abdominal discomfort, nausea and vomiting was not significantly different between groups. Rash was more common in placebo treated patients.<BR/>Local injection-site reactions included any of the following: itching (relative risk = 8.28 [4.99, 13.73] p &lt;0.00001]), swelling (relative risk = 4.01 [2.67, 6.03], p &lt;0.00001]), redness or erythema (relative risk = 4.58 [3.58, 5.88], p &lt;0.0001]) and pain (relative risk = 2.46 [2.05, 2.95], p &lt;0.00001]).<BR/>No adverse events leading to patient's death or major toxicity were reported. One study (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>) mentioned the occurrence of "serious adverse experiences" in 10 glatiramer acetate treated and 6 placebo patients, respectively, but these unspecified events were classified as unrelated to treatment.<BR/>Side effects causing treatment discontinuation were observed in three trials (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>, <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>, <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), but their relation with glatiramer acetate is not definitely established (relative risk = 1.44 [0.94, 2.23], p=0.10] (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<P>Side effects were similar in oral GA -treated and placebo patients , mainly involving the gastrointestinal and nervous system: headache,asthenia, pain, depression, accidental injury,paraesthesia, nausea,abdominal pain, arthralgia, back pain, diarrhoea, constipation, anxiety and dyspepsia (<LINK REF="STD-Filippi-2006" TYPE="STUDY">Filippi 2006</LINK>).</P>
<P>
<B>SECONDARY OUTCOMES</B>
</P>
<P>HOSPITALISATIONS AT THE END OF FOLLOW-UP</P>
<P>Data from hospital admission rates at nine or 35 months were extracted from two studies and 449 patients [<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>]. Hospitalisations were significantly decreased in the glatiramer acetate group: relative risk = 0.60 (95% CI [0.40 to 0.91, p = 0.02]) ( <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>STEROID COURSES AT THE END OF FOLLOW-UP</P>
<P>Two studies evaluated the number of administered steroid cycles on a total of 345 patients. In RR MS at nine months (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>;) a significantly lower number in the glatiramer acetate arm was found relative risk = 0.69 (95% CI [0.55 to 0.87, p = 0.001])( <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> ). In progressive MS at 2 years (<LINK REF="STD-Bornstein-1991" TYPE="STUDY">Bornstein 1991</LINK>), the steroid treatment was administered in 7/55 in the placebo group and 8/51 in GA treated group (data unknown).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-04-14 11:19:58 +0200" MODIFIED_BY="[Empty name]">
<P>We have undertaken this systematic review to explore the amount of evidence currently supporting the use of glatiramer acetate in the management of MS. Our pragmatic approach to include all MS candidates for the administration of this agent, whatever the disease pattern, was aimed at collecting and reviewing all available data on this compound. Unfortunately, we should remark that 22 years after the first randomised pilot trial (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>) information on efficacy of glatiramer acetate did not move so far ahead from the original phase III database. On the other hand, the few completed, company-supported RCTs available are rather homogeneous in their protocols and treatment schedules. It is probable that other RCTs evaluating glatiramer acetate efficacy versus placebo will be no more available since serious ethical concerns regarding the use of placebo when approved therapies are available (<LINK REF="REF-McFarland-2008" TYPE="REFERENCE">McFarland 2008</LINK>).</P>
<P>The first outcome of interest considered in this review, i.e. disease progression, seems unaffected by daily glatiramer acetate administration up to 35 months (RR MS) or 3 years (P MS). It should be noted that all studies required only three months of sustained EDSS worsening to classify patient outcome as a progression, instead of six months as it was established in the review protocol. Althought we had to accept this definition given in the original papers, we cannot exclude that some patients classified as developing progression may actually have experienced a prolonged relapse (transient treatment failure), since the adopted criterion was not able to capture permanent treatment failure, that is irreversible disability (<LINK REF="REF-Rio-2002" TYPE="REFERENCE">Rio 2002</LINK> ). It should be noticed, however, that concern about validity of clinical surrogates of unremitting disability used in MS trials has been recently raised (<LINK REF="REF-Ebers-2008" TYPE="REFERENCE">Ebers 2008</LINK>). However, no data are till now available on the shift to secondary progression phase in RR MS- GA treated patients of the included studies.</P>
<P>When average EDSS changes versus baseline are analysed, a slight improvement in EDSS score has been shown at two years, and at about three years in RR. These results may suggest that GA reduces residual relapse-related disability. Some remarks, however, should be taken into account. We should balance these findings against the reliability of blinding when evaluating glatiramer acetate-treated patients, given a two to five fold increase in injection-site reactions. The more sensitive the endpoint, the more exposed to insufficient masking would be the results. Again, EDSS score is an ordinal scale and it would be more appropriate to analyse it as a threshold to detect disease progression rather than calculating a mean difference. Finally, combined results on clinical improvement are driven by a single largest trial (<LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>), accounting itself for up to 87% of data.<BR/>
<BR/>Benefit of glatiramer acetate on clinical relapses seems to be more consistent. However, an increase of probability (28%) to remain free of relapse was found at 1 year but no more detectable in the follow-up. The mean number of relapses was reduced over time from 1 to 3 years. These results should be considered with caution due to a significant heterogeneity among included trials. When the average number of relapses is considered, results are no better after correcting for heterogeneity. This heterogeneity might reflect differences in patient selection, since risk estimates of controls (basal risks) appear uneven across studies. Using a random effects model, no significant decrease in the average relapse counts can be observed at one year and two years, while a single study suggests that the frequency of relapses experienced at three years could be slightly reduced by less than one, on average, in glatiramer acetate-treated patients. In this respect, it should be noted that the weighted mean difference may not be an appropriate measure to analyse relapse counts. Actually, this variable seems to follow a positive asymmetric distribution (standard deviations tend to increase with increasing mean values across studies) rather than approximating the normal function, as it is assumed by the weighted mean difference analysis.</P>
<P>A recent meta-analysis from Boneschi et al. (<LINK REF="REF-Boneschi-2003" TYPE="REFERENCE">Boneschi 2003</LINK>) of glatiramer acetate trials in patients with RRMS, based on the same trials we have included in this review (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>; <LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), has found a statistically significant difference between glatiramer acetate and placebo as to the following endpoints:<BR/>
</P>
<UL>
<LI>adjusted annualised relapse rate,</LI>
<LI>adjusted risk ratio for the on-trial total number of relapses,</LI>
<LI>time to first relapse.</LI>
</UL>
<P>Actually, Boneschi and co-workers developed a multiple regression model where all raw data from enrolled patients have been pooled, irrespectively from differences across trials. His model has been used to select those covariates significantly associated with the concerned outcome measures. Based on such covariates as "clinical predictors of outcome", adjusted estimates of treatment effect are provided to test treatment efficacy. Unfortunately, the Authors do not mention how much of the total variance is explained by the model in order to support the introduction of data-driven covariates.</P>
<P>In the paper from Boneschi et al. (<LINK REF="REF-Boneschi-2003" TYPE="REFERENCE">Boneschi 2003</LINK>), Kaplan -Meyer estimates of the survival function over a three-year period are also shown, but their denominators are not given along the curve, so that we miss any information on censored data. We know from study protocols that 239 patients completed the study after 9 months (<LINK REF="STD-Comi-2001" TYPE="STUDY">Comi 2001</LINK>), 98 patients after 2 years (<LINK REF="STD-Bornstein-1987" TYPE="STUDY">Bornstein 1987</LINK>; <LINK REF="STD-Johnson-1995" TYPE="STUDY">Johnson 1995</LINK>) and only 203 out of 540 initially enrolled patients have been followed up for 3 years. So, apparently less than 40% of randomised patients contribute to the overall estimate of time to first relapse, but we really cannot say. Indeed, it has been emphasized that "Boneschi and colleagues had access to the raw data from all 540 patients in these studies, whereas Munari and co-workers had access to only the results from those subsets of these data that were published in the original article" (<LINK REF="REF-Caramanos-2005" TYPE="REFERENCE">Caramanos 2005</LINK>). However, since the total number of RRMS patients included in our review counts 540, it would be surprising if data published in peer-review journals would miss some relevant information available in the original phase III data set. Further details on the debate around Boneschi's study and this review is also available in the literature (<LINK REF="REF-Caramanos-2005" TYPE="REFERENCE">Caramanos 2005</LINK>; <LINK REF="REF-Comi-2005" TYPE="REFERENCE">Comi 2005</LINK>; <LINK REF="REF-Munari-2005" TYPE="REFERENCE">Munari 2005</LINK>).<BR/>
<BR/>As regards adverse events, no major toxicity was observed. Reactions are predominantly localised to the injection site or self-limiting. The most common side effect is a combination of flushing, chest tightness, sweating, palpitations, anxiety, referred to as "patterned reaction" and it cannot be considered a harmful event. We have found a little higher incidence (24% of glatiramer acetate-treated patients and 7% of those taking placebo) than reported in the literature (15% and 5%). Rare side effects, however, cannot be explored in phase III trial settings and deserve a careful post-marketing surveillance (<LINK REF="REF-Mancardi-2000" TYPE="REFERENCE">Mancardi 2000</LINK>). Lipoatrophy, for instance, has been observed in some patients after prolonged injections of glatiramer acetate. Following scattered reports in the literature (<LINK REF="REF-Drago-1999" TYPE="REFERENCE">Drago 1999</LINK>; <LINK REF="REF-Hwang-2001" TYPE="REFERENCE">Hwang 2001</LINK>), this finding has been described in 34 out of a case series of 76 patients treated with glatiramer acetate, involving at least one injection site (<LINK REF="REF-Edgar-2004" TYPE="REFERENCE">Edgar 2004</LINK>). Skin lesions, however, were usually mild and only 5 and 9 patients developed severe or moderate lipoatrophy, respectively.</P>
<P>Secondary endpoint analysis supports a decrease in hospital admission rates and steroid courses related to glatiramer acetate treatment. Despite increasing speculation on process endpoints in pharmacoeconomics models, it should be noted that<BR/>
</P>
<UL>
<LI>they are strictly related to the local healthcare financing system;</LI>
<LI>they reflect healthcare policies rather than consumers' needs;</LI>
<LI>they ultimately depend on physician's choices. For instance, treating neurologists may tend to manage more aggressively patients that were not given a presumably beneficial therapy.</LI>
</UL>
<P>
<BR/>Therefore, both hospitalisation and virtually costless steroids are actually of little help in estimating the economic profile of glatiramer acetate.</P>
<P>It has been recently suggested that the evaluation of MRI parameters in trials of MS may introduce an objective measure of treatment effect (<LINK REF="STD-Sormani-2002" TYPE="STUDY">Sormani 2002</LINK>). MRI parameters are still surrogates of therapeutic efficacy and cannot represent a therapeutic goal themselves. Moreover, according to Prentice's validity criteria (<LINK REF="REF-Prentice-1989" TYPE="REFERENCE">Prentice 1989</LINK>), surrogate endpoints should fully capture the net effect of treatment on clinical outcomes, and this cannot be shown in the absence of a significant clinical benefit (<LINK REF="REF-Munari-2004a" TYPE="REFERENCE">Munari 2004a</LINK>
</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-01-26 16:00:01 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-01-26 16:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>Glatiramer acetate seems to have no beneficial effect on the first outcome measure in this disease, i.e. disease progression. The efficacy on relapse-related clinical outcomes seems to be more consistent, but the entity of the effect appear to be light. Its use on RRMS should be considered taking into account its partial efficacy. The therapy is not suitable for progressive MS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-04 15:38:09 +0100" MODIFIED_BY="[Empty name]">
<P> Future studies on glatiramer acetate should taken into consideration with the following issues:<BR/>
</P>
<UL>
<LI>undertake a really blind assessment of patients treated with subcutaneous glatiramer acetate</LI>
<LI>develop a sensitive, comprehensive and reliable measure of patient disability over time</LI>
<LI>establish a unique and reliable clinical definition of patient progression</LI>
</UL>
<UL>
<LI>make definitely clear the relationship between MRI parameters and clinical outcomes fully accomplishing Prentice criteria (<LINK REF="REF-Prentice-1989" TYPE="REFERENCE">Prentice 1989</LINK>).</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-01-13 12:11:06 +0100" MODIFIED_BY="[Empty name]">
<P>Reviewers wish to thank Prof Boiko (Professor in the Department of Neurology and Neurosurgery of the Russian State Medical University) who gave the idea of the review and wrote a first draft version of the protocol, Prof. George Rice (Dept. of Clinical Neurological Sciences, University of Western Ontario, London, Ontario) and Dr. Graziella Filippini (Neuroepidemiology Unit and MS Cochrane Review Group, Ist. Nazionale Neurologico C. Besta, Milan, Italy) for their support in collecting data and appreciated remarks. We thank Deirdre Beecher Trials Search Coordinator for her support on papers retrieval and Liliana Coco Managing Editor for her precious technical assistance and support in drawing up the paper.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-11-05 10:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>L. Munari held a number of conferences on its methodology and results. Some of these meetings were sponsored by Biogen Idec, Canada.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-04-14 11:07:15 +0200" MODIFIED_BY="[Empty name]">
<P>RL, LM ,LLM carried out double-checked data extraction. LM wrote the protocol and text of the review, integrating AB and RL comments and remarks. LLM was charged for updating the review and wrote the final version, integrating new data and co-authors comments.</P>
<P>L. Munari, who wrote the first published version of this review, Neurologist and Statistician, has been Chief Medical Officer at the Azienda Ospedaliera Niguarda Ca' Granda, Milan, Italy.<BR/>R. Lovati is an independent practicing physician participating in the activities of the Neuroepidemiology Unit and MS Cochrane Review Group at the Ist. Nazionale Neurologico C. Besta, Milan, Italy; Dr Lovati is at present working in Oncology Department of S Paolo Hospital, Milan.<BR/>
</P>
<P>L.La Mantia is a senior neurologist involved in MS diagnosis and treatment within the MS center of Neurological Instute C. Besta from many years. She participated to many national and international trials and clinical -immunological studies in MS patients.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2009-09-28 22:14:19 +0200" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-04-14 11:18:47 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-01-26 16:16:13 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-11-10 09:49:34 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bornstein-1987" MODIFIED="2009-07-22 17:56:16 +0200" MODIFIED_BY="[Empty name]" NAME="Bornstein 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-07-22 17:56:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E et al</AU>
<TI>A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<NO>7</NO>
<PG>408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bornstein-1991" MODIFIED="2009-07-22 17:56:42 +0200" MODIFIED_BY="[Empty name]" NAME="Bornstein 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-22 17:56:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M et al</AU>
<TI>A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1991</YR>
<VL>41</VL>
<PG>533-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comi-2001" MODIFIED="2009-11-02 20:05:33 +0100" MODIFIED_BY="Deirdre M Beecher" NAME="Comi 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-01 09:59:11 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Comi G, Filippi M; and-The CM-S-G. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. Neurology 1999;1999;52(Suppl 2):A289&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 09:59:11 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comi G, Filippi M for The Copaxone MRI study Group, Milan Italy</AU>
<TI>The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52 Suppl 2</VL>
<PG>A289</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 18:04:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comi G, Filippi M, Wolinsky J</AU>
<TI>The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in relapsing-remitting multiple sclerosis</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2001</YR>
<VL>Suppl 1</VL>
<PG>187</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-02 20:05:12 +0100" MODIFIED_BY="Deirdre M Beecher" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Comi G, Filippi M, Wolinsky JS and the European/Canadian Glatiramer Acetate Study Group</AU>
<TI>European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2001</YR>
<VL>149</VL>
<NO>3</NO>
<PG>290 -7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into &amp;quot;black holes&amp;quot;. Glatiramer acetate reduces the proportion of new MS lesions evolving into &amp;quot;black holes&amp;quot;. Neurology 2001;57(4):731-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G</AU>
<TI>Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes"</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>4</NO>
<PG>731-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-02 20:05:33 +0100" MODIFIED_BY="Deirdre M Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E et al</AU>
<TI>Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial</TI>
<SO>Multiple Sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>502-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rovaris M, Comi G, Wolinsky JS, Filippi M. The effect of glatiramer acetate on brain volume changes in patients with relapsing-remitting multiple sclerosis. The effect of glatiramer acetate on brain volume changes in patients with relapsing-remitting multiple sclerosis. JNS 2001;187(Suppl.1)&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:30:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovaris M, Comi G, Wolinsky JS, Filippi M</AU>
<TI>The effect of glatiramer acetate on brain volume changes in patients with relapsing-remitting multiple sclerosis</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2001</YR>
<VL>94 Suppl 1</VL>
<PG>187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filippi-2006" MODIFIED="2009-11-02 20:05:55 +0100" MODIFIED_BY="Deirdre M Beecher" NAME="Filippi 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-02 20:05:55 +0100" MODIFIED_BY="Deirdre M Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filippi M, Wolinsky JS, Comi G</AU>
<TI>Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study</TI>
<SO>Lancet Neurology</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-02 20:00:17 +0100" MODIFIED_BY="Deirdre M Beecher" PRIMARY="NO" TYPE="OTHER">
<AU>Markowitz C</AU>
<TI>A multinational, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of 2 doses of glatiramer acetate orally administered in relapsing remitting multiple sclerosis patients</TI>
<SO>http://www.uphs.upenn.edu/neuro/clintrial/MS-Coral-Markowitz.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 18:07:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi M</AU>
<TI>Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study</TI>
<SO>Journal of neurology</SO>
<YR>2008</YR>
<VL>255</VL>
<PG>1378-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1995" MODIFIED="2009-11-10 09:49:34 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-22 18:07:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brochet, B</AU>
<TI>Long-term effects of glatiramer acetate in multiple sclerosis</TI>
<SO>Revue Neurologique</SO>
<YR>2008</YR>
<VL>164</VL>
<PG>917-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 18:08:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ge Y, Grossman RI; Udupa JK; et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;54:813-817 2000;813-817.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 18:08:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales - Scarano F et al</AU>
<TI>Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>4</NO>
<PG>813-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:38:16 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Johnson. Extended use of glatiramer acetate (Copaxone) for MS [Letter]. Extended use of glatiramer acetate (Copaxone) for MS [Letter]. Neurology 1999;1999;52:897-898.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 09:38:16 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenstein JI</AU>
<TI>Extended use of glatiramer acetate (Copaxone) for MS [Letter]</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>4</NO>
<PG>897-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:38:21 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al</AU>
<TI>Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double.-blind, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>7</NO>
<PG>1268-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:38:26 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al</AU>
<TI>Extended use of glatiramer acetate (copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>3</NO>
<PG>701-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, et al</AU>
<TI>Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group</TI>
<SO>Multiple Sclerosis</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>4</NO>
<PG>255-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 18:08:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, et al</AU>
<TI>Glatiramer acetate (Copaxone) : comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial</TI>
<SO>Multiple Sclerosis</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>585-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:39:00 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Johnson KP, Copolymer Multiple Sclerosis Treatment Group. Effects of copolymer on neurologic disability in patients with relapsing-remitting multiple sclerosis: results of a phase III trial. Effects of copolymer on neurologic disability in patients with relapsing-remitting multiple sclerosis: results of a phase III trial. Journal of Neurology 1995;242:S38-S38(Abstract) 1995;(Abstract)&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 09:39:00 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Copolymer Multiple Sclerosis Treatment Group</AU>
<TI>Effects of copolymer on neurologic disability in patients with relapsing-remitting multiple sclerosis: results of a phase III trial [Abstract]</TI>
<SO>Journal of Neurology</SO>
<YR>1995</YR>
<VL>242</VL>
<PG>S38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:39:23 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Johnson KP. Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1. Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1. Ann Neurol 1994;36 Suppl:S115-7.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 09:39:23 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP</AU>
<TI>Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1</TI>
<SO>Annals Neurology</SO>
<YR>1994</YR>
<VL>36 Suppl</VL>
<PG>S115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:40:15 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Johnson KP. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone). Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone). Mult Scler 1996;1(6):325-6.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 09:40:15 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP</AU>
<TI>Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone)</TI>
<SO>Multiple Sclerosis</SO>
<YR>1996</YR>
<VL>1</VL>
<NO>6</NO>
<PG>325-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-01 09:40:34 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Johnson KP. The U.S.Phase III Copolymer 1 Study Group. Antibodies to Copolymer 1 do not interfere with the clinical effect. The U.S.Phase III Copolymer 1 Study Group. Antibodies to Copolymer 1 do not interfere with the clinical effect. Ann Neurol 1995;38:973-973 (Abstract) 1995;(Abstract)&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 09:40:34 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP</AU>
<TI>The U.S.Phase III Copolymer 1 Study Group. Antibodies to Copolymer 1 do not interfere with the clinical effect [Abstract]</TI>
<SO>Annals of Neurology</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>973</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-20 15:43:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu C, Blumhardt LD</AU>
<TI>Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>2000</YR>
<VL>181</VL>
<NO>1-2</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 18:09:06 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Schiffer RB, Johnson KP; Brooks BR; et al. Copolymer-1 reduces the relapse rate and positively influences disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center double-blind, placebo- controlled trial. Copolymer-1 reduces the relapse rate and positively influences disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center double-blind, placebo- controlled trial. European Journal of Neurology 1995;2:103-103 (Abstract) 1995;(Abstract)&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 18:09:06 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffer RB, Johnson KP, Brooks BR, Cohen J, Ford CC, Goldstein J et al</AU>
<TI>Copolymer-1 reduces the relapse rate and positively influences disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center double-blind, placebo- controlled trial [Abstract]</TI>
<SO>European Journal of Neurology</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 09:49:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwid, SR, Goodman, AD, Weinstein, A, McDermott, MP, Johnson, KP</AU>
<TI>Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial</TI>
<SO>Journal of the neurological sciences</SO>
<YR>2007</YR>
<VL>255</VL>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolinsky-2007" MODIFIED="2009-11-03 10:13:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wolinsky 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-03 10:13:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Markowitz C</AU>
<TI>A multinational, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate for injection in primary progressive multiple sclerosis patients</TI>
<SO>http://www.uphs.upenn.edu/neuro/clintrial/MS-Promise-Markowitz.htm</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-02 20:08:42 +0100" MODIFIED_BY="Deirdre M Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sajja BR, Narayana PA, Wolinsky JS , Ahn CW and the PROMiSe trial</AU>
<TI>longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate : multicenter study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-07 14:02:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K et al</AU>
<TI>Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial</TI>
<SO>Annals of neurology</SO>
<YR>2007</YR>
<VL>61</VL>
<PG>14-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-20 16:32:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolinsky JS</AU>
<TI>The PROMiSe trial: baseline data review and progress report</TI>
<SO>Multiple Sclerosis</SO>
<YR>2004</YR>
<VL>10 Suppl 1</VL>
<PG>S65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-01-26 16:16:13 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abramsky-1977" MODIFIED="2009-10-18 15:15:27 +0200" MODIFIED_BY="[Empty name]" NAME="Abramsky 1977" YEAR="1977">
<REFERENCE MODIFIED="2009-10-18 15:15:27 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J Neurol Sci 1977;31(3):433-8.&lt;/p&gt;" NOTES_MODIFIED="2009-10-18 15:15:27 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abramsky O, Teitelbaum D, Arnon R</AU>
<TI>Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1977</YR>
<VL>31</VL>
<NO>3</NO>
<PG>433-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Achiron-2005" MODIFIED="2009-07-22 16:31:50 +0200" MODIFIED_BY="[Empty name]" NAME="Achiron 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:31:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R et al</AU>
<TI>Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments</TI>
<SO>Breast cancer research and treatment</SO>
<YR>2005</YR>
<VL>89</VL>
<PG>265-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnold-2008" MODIFIED="2009-07-22 16:32:09 +0200" MODIFIED_BY="[Empty name]" NAME="Arnold 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:32:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnold DL, Campagnolo D, Panitch H. Bar-Or A, Dunn J, Freedman M et al</AU>
<TI>Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in Multiple Sclerosis</TI>
<SO>Journal of neurology</SO>
<YR>2008</YR>
<VL>255</VL>
<PG>1473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ball-2008" MODIFIED="2009-07-22 17:28:04 +0200" MODIFIED_BY="[Empty name]" NAME="Ball 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:32:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ball NJ, Cowan BJ, Moore GR, Hashimoto SA</AU>
<TI>Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases</TI>
<SO>Journal of cutaneous pathology</SO>
<YR>2008</YR>
<VL>35</VL>
<PG>407-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumhefner-1988" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Baumhefner 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Baumhefner RW, Tourtellotte WW, Syndulko K, Shapshak P, Osborne M, Rubinshtein G. Copolymer 1 as therapy for multiple sclerosis: the cons. Copolymer 1 as therapy for multiple sclerosis: the cons. Neurology 1988;38(7 Suppl 2):69-72.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:30:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baumhefner RW, Tourtellotte WW, Syndulko K, Shapshak P, Osborne M, Rubinshtein G</AU>
<TI>Copolymer 1 as therapy for multiple sclerosis: the cons</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38 Suppl 2</VL>
<NO>7</NO>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanco-2006" MODIFIED="2009-07-22 17:27:58 +0200" MODIFIED_BY="[Empty name]" NAME="Blanco 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:33:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blanco Y, Moral EA, Costa M, Gomez-Choco M, Torres-Peraza JF, Alonso-Magdalena L et al</AU>
<TI>Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study</TI>
<SO>Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study</SO>
<YR>2006</YR>
<VL>406</VL>
<PG>270-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boiko-2006" MODIFIED="2009-07-22 17:27:51 +0200" MODIFIED_BY="[Empty name]" NAME="Boiko 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 17:27:05 +0200" MODIFIED_BY="[Empty name]" NOTES="RUSSIAN; emailed author 16/06/09" NOTES_MODIFIED="2009-07-22 17:27:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boiko AN, Davydovskaia MF, Demina TL, Lashch NI, Ovcharov VV, Popova NF, et al</AU>
<TI>[The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy]</TI>
<SO>Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova / Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov.</SO>
<YR>2006</YR>
<VL>Spec No 3</VL>
<PG>101-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bornstein-1982" MODIFIED="2008-09-01 10:11:09 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bornstein 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-09-01 10:11:09 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 1982;11(3):317-9.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:11:09 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M</AU>
<TI>Multiple sclerosis: trial of a synthetic polypeptide</TI>
<SO>Annals of Neurology</SO>
<YR>1982</YR>
<VL>11</VL>
<NO>3</NO>
<PG>317-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosca-2006" MODIFIED="2009-07-22 19:02:11 +0200" MODIFIED_BY="[Empty name]" NAME="Bosca 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:34:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosca I, Bosca M, Belenguer A, Evole M, Hernandez M, Casanova B, et al</AU>
<TI>Necrotising cutaneous lesions as a side effect of glatiramer acetate</TI>
<SO>Journal of neurology</SO>
<YR>2006</YR>
<VL>253</VL>
<PG>1370-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brenner-2001" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Brenner 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven_Kreitman R, Tarcik N, Teitelbaum D. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115(1-2):152-60.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:30:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, RivenKreitman R et al</AU>
<TI>Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>2001</YR>
<VL>115</VL>
<NO>1-2</NO>
<PG>152-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brochet-2008" MODIFIED="2009-07-22 16:34:45 +0200" MODIFIED_BY="[Empty name]" NAME="Brochet 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:34:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brochet, B</AU>
<TI>Long-term effects of glatiramer acetate in multiple sclerosis</TI>
<SO>Revue Neurologique</SO>
<YR>2008</YR>
<VL>164</VL>
<PG>917-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cadavid-2009" MODIFIED="2009-07-22 17:31:08 +0200" MODIFIED_BY="[Empty name]" NAME="Cadavid 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-22 17:31:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K et al</AU>
<TI>Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>23</NO>
<PG>1972-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caon-2006" MODIFIED="2009-07-22 16:35:30 +0200" MODIFIED_BY="[Empty name]" NAME="Caon 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:35:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O</AU>
<TI>Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis</TI>
<SO>European journal of neurology</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>471-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capobianco-2008" MODIFIED="2009-07-22 16:35:45 +0200" MODIFIED_BY="[Empty name]" NAME="Capobianco 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:35:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capobianco M, Rizzo A, Malucchi S, Sperli F, Di Sapio A, Oggero A, et al</AU>
<TI>Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients</TI>
<SO>Neurological sciences</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>S227-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carra-2008" MODIFIED="2009-07-22 16:36:00 +0200" MODIFIED_BY="[Empty name]" NAME="Carra 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:36:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carra A, Onaha P, Luetic G., Burgos M, Crespo E, Deri N, et al</AU>
<TI>Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina</TI>
<SO>European journal of neurology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>386-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castelli_x002d_Haley-2008" MODIFIED="2009-07-22 16:36:16 +0200" MODIFIED_BY="[Empty name]" NAME="Castelli-Haley 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:36:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP</AU>
<TI>Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patient</TI>
<SO>Advances in therapy</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>658-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charach-2008" MODIFIED="2009-11-10 09:48:06 +0100" MODIFIED_BY="[Empty name]" NAME="Charach 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-10 09:48:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charach G, Grosskopf I, Weintraub M</AU>
<TI>Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone</TI>
<SO>Digestion</SO>
<YR>2008</YR>
<VL>77</VL>
<PG>198-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2001" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Chen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib_Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001;7(4):209-19.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:30:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S</AU>
<TI>Glatiramer acetate induces a Th2-biased response and cross reactivity with myelin basic protein in patients with MS</TI>
<SO>Multiple Sclerosis</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>4</NO>
<PG>209-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-02 22:42:04 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cicek-2008" MODIFIED="2009-07-22 16:36:51 +0200" MODIFIED_BY="[Empty name]" NAME="Cicek 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:36:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicek D, Kandi B, Oguz S, Cobanoglu B, Bulut S, Saral Y</AU>
<TI>An urticarial vasculitis case induced by glatiramer acetate</TI>
<SO>The Journal of dermatological treatment</SO>
<YR>2008</YR>
<VL>19</VL>
<PG>305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1995" MODIFIED="2009-07-22 16:37:01 +0200" MODIFIED_BY="[Empty name]" NAME="Cohen 1995" YEAR="1995;">
<REFERENCE MODIFIED="2009-07-22 16:37:01 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cohen JA, Grossman RI; Udupa JK; et al. Assessment of the efficacy of Copolymer-1 in the Treatment of Multiple Sclerosis by Quantitative MRI. Assessment of the efficacy of Copolymer-1 in the Treatment of Multiple Sclerosis by Quantitative MRI. Neurology 1995;45 (Suppl 1995;4)(Abstract)&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:37:01 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JA, Grossman RI, Udupa JK, Smatasekera S, Miki Y, Polansky M et al</AU>
<TI>Assessment of the efficacy of Copolymer-1 in the Treatment of Multiple Sclerosis by Quantitative MRI</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45 Suppl 4</VL>
<PG>A470</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2007" MODIFIED="2009-07-22 16:37:20 +0200" MODIFIED_BY="[Empty name]" NAME="Cohen 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:37:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi MT</AU>
<TI>Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>68 </VL>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Constantinescu-2000" MODIFIED="2008-09-01 10:12:17 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Constantinescu 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-01 10:12:17 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000;6(6):378-81.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:12:17 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Constantinescu CS, Freitag P, Kappos L</AU>
<TI>Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>6</NO>
<PG>378-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daugherty-2005" MODIFIED="2009-07-22 16:37:38 +0200" MODIFIED_BY="[Empty name]" NAME="Daugherty 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:37:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daugherty KK, Butler JS, Mattingly M, Ryan M</AU>
<TI>Factors leading patients to discontinue multiple sclerosis therapies</TI>
<SO>Journal of the American Pharmacists Association</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>371-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Seze-2000" NAME="De Seze 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;de_Seze J, Edan G, Labalette M, Dessaint JP, Vermersch P. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Ann Neurol 2000;47(5):686&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Seze J, Edan G, Labalette M, Dessaint JP, Vermersch P</AU>
<TI>Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial</TI>
<SO>Annals of Neurology</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>5</NO>
<PG>686</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Stefano-2008" MODIFIED="2009-11-03 10:21:23 +0100" MODIFIED_BY="[Empty name]" NAME="De Stefano 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-03 10:21:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Stefano, N, Filippi, M, Hawkins, C</AU>
<TI>Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis</TI>
<SO>Journal of the neurological sciences</SO>
<YR>2008</YR>
<VL>266</VL>
<NO>1-2</NO>
<PG>44-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Stefano-2009" MODIFIED="2010-01-26 16:16:13 +0100" MODIFIED_BY="[Empty name]" NAME="De Stefano 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-01-26 16:16:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Stefano N, Fillippi M, Confavreux C, Vermesch P, Simu M, Sindic C et al</AU>
<TI>The results of two multicenter open label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymer mixture in patients with relapsing remitting multiple sclerosis</TI>
<SO>multiple sclerosis</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>2</NO>
<PG>238-243</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debouverie-2007" MODIFIED="2009-07-22 16:38:30 +0200" MODIFIED_BY="[Empty name]" NAME="Debouverie 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:38:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Debouverie M, Moreau T, Lebrun C, Heinzlef O, Brudon F, Msihid J</AU>
<TI>A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate</TI>
<SO>European journal of neurology</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>1266-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deen-2008" MODIFIED="2009-07-22 16:38:45 +0200" MODIFIED_BY="[Empty name]" NAME="Deen 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:38:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deen S, Bacchetti P, High A, Waubant E </AU>
<TI>Predictors of the location of multiple sclerosis relapse</TI>
<SO>Journal of neurology, neurosurgery, and psychiatry</SO>
<YR>2008</YR>
<VL>79</VL>
<PG>1190-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duda-2000" MODIFIED="2008-09-01 10:12:29 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Duda 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-01 10:12:29 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105(7):967-76.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:12:29 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA</AU>
<TI>Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>7</NO>
<PG>967-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farina-2001" MODIFIED="2009-07-22 16:30:49 +0200" MODIFIED_BY="[Empty name]" NAME="Farina 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-01 10:12:38 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Farina C, Bergh FT, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, Hohlfeld R. Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001;124(4):705-19.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:12:38 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farina C, Bergh FT, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, Hohlfeld R</AU>
<TI>Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<NO>4</NO>
<PG>705-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 16:30:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovaris, M, Comi, G, Filippi, M</AU>
<TI>Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?</TI>
<SO>Journal of the neurological sciences</SO>
<YR>2005</YR>
<VL>233</VL>
<PG>139</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feigin-2005" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Feigin 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feigin, PD</AU>
<TI>On cancer incidence in multiple sclerosis and effects of immunomodulatory treatments</TI>
<SO>Breast cancer research and treatment</SO>
<YR>2005</YR>
<VL>92</VL>
<PG>197</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiore-2005" MODIFIED="2009-07-22 16:39:23 +0200" MODIFIED_BY="[Empty name]" NAME="Fiore 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:39:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiore AP, Fragoso YD</AU>
<TI>Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six month</TI>
<SO>Arquivos de Neuro-psiquiatria</SO>
<YR>2005</YR>
<VL>63</VL>
<PG>738-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flechter-2002a" MODIFIED="2008-09-01 10:12:46 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Flechter 2002a" YEAR="2002">
<REFERENCE MODIFIED="2008-09-01 10:12:46 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Flechter S, Kott E, Steiner_Birmanns B, Nisipeanu P, Korczyn AD. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Clin Neuropharmacol 2002;25(1):11-5.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:12:46 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flechter S, Kott E, Steiner-Birmanns B, Nisipeanu P, Korczyn AD</AU>
<TI>Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>1</NO>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flechter-2002b" MODIFIED="2008-09-01 10:12:52 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Flechter 2002b" YEAR="2002">
<REFERENCE MODIFIED="2008-09-01 10:12:52 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002;197(1-2):51-5.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:12:52 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flechter S, Vardi J, Pollak L, Rabey JM</AU>
<TI>Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>2002</YR>
<VL>197</VL>
<NO>1-2</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ford-2006" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Ford 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ford, CC, Johnson, KP, Lisak, RP, Panitch, HS, Shifronis, G, Wolinsky, JS</AU>
<TI>A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patient</TI>
<SO>Multiple Sclerosis</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>309-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fusco-2001" MODIFIED="2009-07-22 16:40:02 +0200" MODIFIED_BY="[Empty name]" NAME="Fusco 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-22 16:40:02 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E, Florio C, Pirozzi G, Lanzillo R, Ferrante P, et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001;57(11):1976-9.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:40:02 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E et al</AU>
<TI>HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>11</NO>
<PG>1976-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gajofatto-2009" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Gajofatto 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gajofatto, A, Bacchetti, P, Grimes, B, High, A, Waubant, E</AU>
<TI>Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis</TI>
<SO>Multiple sclerosis</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>50-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Barragan-2009" MODIFIED="2009-07-22 16:40:35 +0200" MODIFIED_BY="[Empty name]" NAME="Garcia-Barragan 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-22 16:40:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Barragan N, Villar LM, Espino M, Sadaba MC, Gonzalez-Porque P, Alvarez-Cermeno JC</AU>
<TI>Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment</TI>
<SO>European journal of neurology</SO>
<YR>2009</YR>
<VL>16</VL>
<PG>380-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghezzi--b-2005" MODIFIED="2009-07-22 16:40:49 +0200" MODIFIED_BY="[Empty name]" NAME="Ghezzi  b 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:40:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V et al</AU>
<TI>Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study</TI>
<SO>Multiple Sclerosis</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>420-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghezzi-2005" MODIFIED="2009-07-22 16:41:00 +0200" MODIFIED_BY="[Empty name]" NAME="Ghezzi 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:41:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group</AU>
<TI>Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study</TI>
<SO>Neurological sciences</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>4</NO>
<PG>S183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-2009" MODIFIED="2009-07-22 16:41:23 +0200" MODIFIED_BY="[Empty name]" NAME="Goodman 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-22 16:41:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al</AU>
<TI>GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<PG>806-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas-2005" MODIFIED="2009-07-22 16:41:35 +0200" MODIFIED_BY="[Empty name]" NAME="Haas 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:41:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas J, Firzlaff M</AU>
<TI>Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)</TI>
<SO>European journal of neurology</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>425-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harde-2007" MODIFIED="2009-07-22 16:41:41 +0200" MODIFIED_BY="[Empty name]" NAME="Harde 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:41:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harde V, Schwarz T</AU>
<TI>Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate</TI>
<SO>Journal der Deutschen.Dermatologischen.Gesellschaft</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>1122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2000" MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-22 16:30:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP et al</AU>
<TI>Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.</TI>
<SO>Multiple Sclerosis</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>255-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2003" MODIFIED="2009-07-22 16:41:55 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-22 16:41:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW et al</AU>
<TI>Glatiramer acetate (Copaxone) : comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial</TI>
<SO>Multiple Sclerosis</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>585-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2005" MODIFIED="2009-07-22 16:42:25 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:42:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson KP, Ford CC, Lisak RP, Wolinsky JS</AU>
<TI>Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2005</YR>
<VL>111</VL>
<PG>42-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jolly-2008" MODIFIED="2009-07-22 16:42:53 +0200" MODIFIED_BY="[Empty name]" NAME="Jolly 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:42:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jolly H, Simpson K, Bishop B, Hunter H, Newell C, Denney D et al</AU>
<TI>Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate</TI>
<SO>The Journal of neuroscience nursing</SO>
<YR>2008</YR>
<VL>40</VL>
<PG>232-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karandikar-2002" MODIFIED="2008-09-01 10:13:06 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Karandikar 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-01 10:13:06 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Karandikar NJ, Crawford MP, Yan X, Ratts RB, et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cella response in patients with multiple sclerosis. Glatiramer acetate (Copaxone) therapy induces CD8+ T cella response in patients with multiple sclerosis. Journal of Clinical Investigation 2002;109:641-9.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:13:06 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, et al</AU>
<TI>Glatiramer acetate (Copaxone) therapy induces CD8+ T cella response in patients with multiple sclerosis</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>5</NO>
<PG>641-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2001" MODIFIED="2008-09-01 10:13:19 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Khan 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-01 10:13:19 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001;7(6):349-53.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:13:19 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP</AU>
<TI>A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy</TI>
<SO>Multiple Sclerosis</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>6</NO>
<PG>349-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2005" MODIFIED="2009-07-22 16:43:49 +0200" MODIFIED_BY="[Empty name]" NAME="Khan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:43:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M et al</AU>
<TI>Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis</TI>
<SO>Multiple sclerosis</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>646</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-khan-2008" MODIFIED="2009-07-22 16:44:09 +0200" MODIFIED_BY="[Empty name]" NAME="khan 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:44:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan O, Shen Y, Bao F, Caon C, Tselis A, Latif Z et al</AU>
<TI>Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis</TI>
<SO>Journal of neuroimaging</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>314-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kott-1997" MODIFIED="2009-07-22 17:49:11 +0200" MODIFIED_BY="[Empty name]" NAME="Kott 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-22 17:48:56 +0200" MODIFIED_BY="[Empty name]" NOTES="Handsearch" NOTES_MODIFIED="2009-07-22 17:48:56 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kott E, Kessler A, Biran S</AU>
<TI>Optic Neuritis in Multiple Sclerosis Patients Treated with Copaxone</TI>
<SO>Journal of Neurology</SO>
<YR>1997</YR>
<VL>244</VL>
<PG>S23-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Mantia-2006" MODIFIED="2009-07-22 17:15:22 +0200" MODIFIED_BY="[Empty name]" NAME="La Mantia 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 17:15:00 +0200" MODIFIED_BY="[Empty name]" NOTES="DA - 20060811" NOTES_MODIFIED="2009-07-22 17:15:00 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Mantia L, D'Amico D, Rigamonti A, Mascoli N, Bussone G, Milanese C</AU>
<TI>Interferon treatment may trigger primary headaches in multiple sclerosis patients</TI>
<SO>Multiple sclerosis (Houndmills, Basingstoke, England)</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1352-4585</NO>
<PG>476-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lage-2006" MODIFIED="2009-07-22 17:25:04 +0200" MODIFIED_BY="[Empty name]" NAME="Lage 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 17:23:25 +0200" MODIFIED_BY="[Empty name]" NOTES="NO ACCESS - REQUEST ILL" NOTES_MODIFIED="2009-07-22 17:23:25 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lage MJ, Castelli-Haley J, Oleen-Burkey MA</AU>
<TI>Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis</TI>
<SO>Work (Reading., Mass.)</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>2</NO>
<PG>143-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Page-2008" MODIFIED="2009-07-22 16:45:01 +0200" MODIFIED_BY="[Empty name]" NAME="Le Page 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:45:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey S et al</AU>
<TI>Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients</TI>
<SO>Journal of neurology, neurosurgery, and psychiatry</SO>
<YR>2008</YR>
<VL>79</VL>
<PG>52-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madray-2008" MODIFIED="2009-07-22 16:45:53 +0200" MODIFIED_BY="[Empty name]" NAME="Madray 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:45:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madray MM, Greene JF Jr, Butler, DF</AU>
<TI>Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma</TI>
<SO>Archives of neurology</SO>
<YR>2008</YR>
<VL>65</VL>
<PG>1378-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mancardi-1998" MODIFIED="2008-09-01 10:13:39 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Mancardi 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-01 10:13:39 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, Ferrari A, Sormani MP, Ottonello C, Levrero F, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998;50(4):1127-33.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:13:39 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, et al</AU>
<TI>Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meiner-1997" MODIFIED="2008-09-01 10:14:04 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Meiner 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-01 10:14:04 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Meiner Z, Kott E, Schechter D, et al. Abramsky O, Ovadia H, editors.Frontiers in Multiple Sclerosis: Clinical Research and Therapy. London: Martin Dunitz; 1997;Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-centre trial. p. 213-21.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:14:04 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Meiner Z, Kott E, Schechter D, et al</AU>
<TI>Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-centre trial</TI>
<SO>Frontiers in Multiple Sclerosis: Clinical Research and Therapy</SO>
<YR>1997</YR>
<PG>213-21</PG>
<ED>Abramsky O, Ovadia H</ED>
<PB>Martin Dunitz</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mesaros_x002c_-2008" MODIFIED="2009-07-22 16:46:47 +0200" MODIFIED_BY="[Empty name]" NAME="Mesaros, 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:46:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi, M</AU>
<TI>Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study</TI>
<SO>Journal of neurology</SO>
<YR>2008</YR>
<VL>255</VL>
<PG>1378-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikol-2008" MODIFIED="2009-07-22 16:47:07 +0200" MODIFIED_BY="[Empty name]" NAME="Mikol 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:47:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR et al</AU>
<TI>Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial</TI>
<SO>Lancet neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<PG>903-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milanese-2005" MODIFIED="2009-07-22 16:47:30 +0200" MODIFIED_BY="[Empty name]" NAME="Milanese 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:47:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milanese C, Beghi E, Giordano L, La Mantia L, Mascoli N, Confalonieri P et al</AU>
<TI>A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results</TI>
<SO>Neurological sciences</SO>
<YR>2005</YR>
<VL>26 Suppl 4</VL>
<PG>S171-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1998" MODIFIED="2008-09-01 10:17:27 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Miller 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-01 10:17:27 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998;92(1-2):113-21.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:17:27 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al</AU>
<TI>Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>1-2</NO>
<PG>113-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2006" MODIFIED="2009-07-22 16:47:47 +0200" MODIFIED_BY="[Empty name]" NAME="Miller 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:47:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller CE, Jezewski MA</AU>
<TI>Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study</TI>
<SO>The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses</SO>
<YR>2006</YR>
<VL>38</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2008" MODIFIED="2009-07-22 16:48:03 +0200" MODIFIED_BY="[Empty name]" NAME="Miller 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:48:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller A, Spada V, Beerkircher D, Kreitman RR</AU>
<TI>Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>494-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-2007" MODIFIED="2009-07-22 16:48:27 +0200" MODIFIED_BY="[Empty name]" NAME="Neumann 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:48:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann H, Csepregi A, Sailer M, Malfertheiner PT</AU>
<TI>Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis</TI>
<SO>Journal of neurology</SO>
<YR>2007</YR>
<VL>254</VL>
<PG>816-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolden-2005" MODIFIED="2009-07-22 16:48:37 +0200" MODIFIED_BY="[Empty name]" NAME="Nolden 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:48:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolden S, Casper C, Kuhn A, Petereit HF</AU>
<TI>Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate</TI>
<SO>Multiple sclerosis</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>245-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ollendorf-2008" MODIFIED="2009-07-22 16:48:48 +0200" MODIFIED_BY="[Empty name]" NAME="Ollendorf 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:48:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ollendorf DA, Castelli-Haley J, Oleen-Burkey M</AU>
<TI>Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis</TI>
<SO>The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses</SO>
<YR>2008</YR>
<VL>40</VL>
<PG>281-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orlova-2005" MODIFIED="2009-07-22 17:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Orlova 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 17:23:25 +0200" MODIFIED_BY="[Empty name]" NOTES="RUSSIAN" NOTES_MODIFIED="2009-07-22 17:23:25 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orlova IuIu, Alifirova VM, Cherdyntseva NV, Zagrebina IA, Bychkova IV</AU>
<TI>[3-year results of clinical and immunological monitoring of patients with multiple sclerosis treated by copaxone]</TI>
<SO>Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova / Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov.</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>5</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patten-2008" MODIFIED="2009-07-22 16:49:14 +0200" MODIFIED_BY="[Empty name]" NAME="Patten 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 16:49:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patten SB, Williams JV, Metz LM</AU>
<TI>Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>406-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-P_x00f6_llmann-2006" MODIFIED="2009-07-22 16:49:25 +0200" MODIFIED_BY="[Empty name]" NAME="Pöllmann 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:49:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pöllmann W, Erasmus LP, Feneberg W, Straube A</AU>
<TI>The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<PG>275-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2000" MODIFIED="2009-07-22 16:49:34 +0200" MODIFIED_BY="[Empty name]" NAME="Qin 2000" YEAR="2000;">
<REFERENCE MODIFIED="2009-07-22 16:49:34 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Qin Y, Zhang DQ; Prat A; Pouly S; Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. Journal of Neuroimmunology 2000;108:201-206 2000;201-206.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:49:34 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin Y, Zhang DQ, Prat A, Pouly S, Antel J</AU>
<TI>Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>2000</YR>
<VL>108</VL>
<NO>1-2</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramtahal-2006" MODIFIED="2009-07-22 16:49:46 +0200" MODIFIED_BY="[Empty name]" NAME="Ramtahal 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:49:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramtahal J, Jacob A, Das K, Boggild M</AU>
<TI>Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2006</YR>
<VL>253</VL>
<PG>1160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rauschka-2005" MODIFIED="2009-07-22 16:50:03 +0200" MODIFIED_BY="[Empty name]" NAME="Rauschka 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:50:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rauschka H, Farina C, Sator P, Gudek S, Breier F, Schmidbauer M</AU>
<TI>Severe anaphylactic reaction to glatiramer acetate with specific IgE</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>1481-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rio-2005" MODIFIED="2009-11-10 09:51:07 +0100" MODIFIED_BY="[Empty name]" NAME="Rio 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 09:51:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rio J, Porcel J, Tellez N, Sanchez-Betancourt AT</AU>
<TI>Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis</TI>
<SO>Multiple sclerosis (Houndmills, Basingstoke, England)</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>306-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rovaris-2005" MODIFIED="2009-07-22 16:52:42 +0200" MODIFIED_BY="[Empty name]" NAME="Rovaris 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:52:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovaris M, Comi G, Filippi M</AU>
<TI>Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2005</YR>
<VL>233</VL>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rovaris-2007" MODIFIED="2009-07-22 16:53:02 +0200" MODIFIED_BY="[Empty name]" NAME="Rovaris 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:53:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E</AU>
<TI>Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial</TI>
<SO>Multiple sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>502-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwid-2007" MODIFIED="2009-11-10 09:46:34 +0100" MODIFIED_BY="[Empty name]" NAME="Schwid 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 09:46:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP</AU>
<TI>Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial</TI>
<SO>Journal of the neurological sciences</SO>
<YR>2007</YR>
<VL>255</VL>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shipova-2009" MODIFIED="2009-07-22 16:53:40 +0200" MODIFIED_BY="[Empty name]" NAME="Shipova 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-22 16:53:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shipova EG, Spirin NN, Kasatkin DS, Shumakov EI, Stepanov I O</AU>
<TI>State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment</TI>
<SO>Neuroscience and behavioral physiology</SO>
<YR>2009</YR>
<VL>39</VL>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sidoti-2007" MODIFIED="2009-07-22 16:53:49 +0200" MODIFIED_BY="[Empty name]" NAME="Sidoti 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:53:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sidoti V, Lorusso, L</AU>
<TI>Multiple sclerosis and Capgras' syndrome</TI>
<SO>Clinical neurology and neurosurgery</SO>
<YR>2007</YR>
<VL>109</VL>
<PG>786-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sindic-2005" MODIFIED="2009-07-22 16:54:08 +0200" MODIFIED_BY="[Empty name]" NAME="Sindic 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:54:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP et al</AU>
<TI>Long-term follow up of glatiramer acetate compassionate use in Belgium</TI>
<SO>Acta Neurologica Belgica</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>2</NO>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soares-2006" MODIFIED="2009-07-22 17:31:59 +0200" MODIFIED_BY="[Empty name]" NAME="Soares 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 17:27:05 +0200" MODIFIED_BY="[Empty name]" NOTES="retrieved 12/05/09" NOTES_MODIFIED="2009-07-22 17:27:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soares Almeida LM, Requena L, Kutzner H, Angulo J, de Sa J, Pignatelli J</AU>
<TI>Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>6</NO>
<PG>968-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sormani-2002" MODIFIED="2008-09-01 10:17:43 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Sormani 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-01 10:17:43 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Sormani MP, Bruzzi P, Comi G, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002;58(3):417-21.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:17:43 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sormani MP, Bruzzi P, Comi G, Filippi M</AU>
<TI>MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<NO>3</NO>
<PG>417-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sormani-2005" MODIFIED="2009-07-22 16:54:52 +0200" MODIFIED_BY="[Empty name]" NAME="Sormani 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 16:54:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sormani MP, Bruzzi P, Comi G, Filippi M</AU>
<TI>The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis</TI>
<SO>Multiple sclerosis</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>447-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sormani-2007" MODIFIED="2009-07-22 16:55:03 +0200" MODIFIED_BY="[Empty name]" NAME="Sormani 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:55:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sormani MP, Rovaris M, Comi G, Filippi MT</AU>
<TI>A composite score to predict short-term disease activity in patients with relapsing-remitting MS</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>69</VL>
<PG>1230-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Then_x002c_-Bergh-F-2006" MODIFIED="2009-07-22 16:55:22 +0200" MODIFIED_BY="[Empty name]" NAME="Then, Bergh F 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:55:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J et al</AU>
<TI>Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis</TI>
<SO>Acta Haematologica</SO>
<YR>2006</YR>
<VL>116</VL>
<PG>207-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thouvenot-2007" MODIFIED="2009-07-22 16:55:56 +0200" MODIFIED_BY="[Empty name]" NAME="Thouvenot 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:55:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, Rigau V, Durand L, Guillot B et al</AU>
<TI>Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>941-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tilbery-2006" MODIFIED="2009-07-22 16:56:16 +0200" MODIFIED_BY="[Empty name]" NAME="Tilbery 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 16:56:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tilbery CP, Mendes MF, Oliveira BE, Thomaz RB, Kelian G R</AU>
<TI>Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients</TI>
<SO>Arquivos de Neuro-psiquiatria</SO>
<YR>2006</YR>
<VL>64</VL>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torkildsen-2007" MODIFIED="2009-07-22 17:36:50 +0200" MODIFIED_BY="[Empty name]" NAME="Torkildsen 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 17:36:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torkildsen O, Grytten N, Myhr KM</AU>
<TI>Immunomodulatory treatment of multiple sclerosis in Norway</TI>
<SO>Acta Neurologica Scandinavica. Supplementum</SO>
<YR>2007</YR>
<VL>115</VL>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tremlett-2007" MODIFIED="2009-07-22 16:57:42 +0200" MODIFIED_BY="[Empty name]" NAME="Tremlett 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:57:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torkildsen O, Grytten N, Myhr KM</AU>
<TI>Immunomodulatory treatment of multiple sclerosis in Norway</TI>
<SO>Acta Neurologica Scandinavica. Supplementum</SO>
<YR>2007</YR>
<VL>187</VL>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Twork-2007" MODIFIED="2009-07-22 16:58:28 +0200" MODIFIED_BY="[Empty name]" NAME="Twork 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:58:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Twork S, Nippert I, Scherer P, Haas J, Pohlau D, Kugler J</AU>
<TI>Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population</TI>
<SO>Current medical research and opinion</SO>
<YR>2007</YR>
<VL>23</VL>
<PG>1209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valenzuela-2007" MODIFIED="2009-07-22 16:59:18 +0200" MODIFIED_BY="[Empty name]" NAME="Valenzuela 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 16:59:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S</AU>
<TI>Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis</TI>
<SO>Multiple sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>754-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vallittu-2005" MODIFIED="2009-07-22 17:32:37 +0200" MODIFIED_BY="[Empty name]" NAME="Vallittu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 17:32:37 +0200" MODIFIED_BY="[Empty name]" NOTES="retrieved 12/05/09" NOTES_MODIFIED="2009-07-22 17:32:37 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vallittu AM, Peltoniemi J, Elovaara I, Kuusisto H, Farkkila M, Multanen J, et al</AU>
<TI>The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>4</NO>
<PG>234-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vollmer-2008" MODIFIED="2009-07-22 17:00:41 +0200" MODIFIED_BY="[Empty name]" NAME="Vollmer 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 17:00:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK et al</AU>
<TI>Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis</TI>
<SO>Multiple sclerosis</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>663-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weder-2005" MODIFIED="2009-07-22 17:01:42 +0200" MODIFIED_BY="[Empty name]" NAME="Weder 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 17:01:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weder C, Baltariu GM, Wyler KA, Gober HJ, Lienert C, Schluep M et al</AU>
<TI>Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis</TI>
<SO>European journal of neurology</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>869-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinstein-1999" MODIFIED="2008-09-01 10:17:51 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Weinstein 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-01 10:17:51 +0200" MODIFIED_BY="Deirdre Beecher" NOTES="&lt;p&gt;Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56(3):319-24.&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 10:17:51 +0200" NOTES_MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD</AU>
<TI>Neuropsychologic status in multiple sclerosis after treatment with glatiramer</TI>
<SO>Archives of Neurology</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>3</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolinsky-2001" NAME="Wolinsky 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Wolinsky JS, Narayana PA, Johnson KP. MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Multiple Sclerosis 2001;7(1):33-41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolinsky JS, Narayana PA, Johnson KP</AU>
<TI>MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center</TI>
<SO>Multiple Sclerosis</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>1</NO>
<PG>33-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wynn-2008" MODIFIED="2009-07-22 17:33:34 +0200" MODIFIED_BY="[Empty name]" NAME="Wynn 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 17:27:05 +0200" MODIFIED_BY="[Empty name]" NOTES="NO ACCESS - REQUEST ILL" NOTES_MODIFIED="2009-07-22 17:27:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wynn D, Meyer C, Allen N, O'Brien D</AU>
<TI>Optimal dosing of immunomodulating drugs: A dose-comparison study of GA in RRMS</TI>
<SO>Progress in Neurotherapeutics and Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>1</NO>
<PG>137-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ytterberg-2007" MODIFIED="2009-07-22 17:06:15 +0200" MODIFIED_BY="[Empty name]" NAME="Ytterberg 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 17:06:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ytterberg C, Johansson S, Andersson M, Olsson D, Link, H, Holmqvist LW, von Koch L</AU>
<TI>Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2007</YR>
<VL>116</VL>
<PG>96-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zavalishin-2005" MODIFIED="2009-09-19 15:12:49 +0200" MODIFIED_BY="[Empty name]" NAME="Zavalishin 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-19 15:12:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zavalishin, I. A., Peresedova, A. V., Stoida, N. I., Adarcheva, L. S., Zakharova, M. N., Niiazbekova, A. S., Askarova, L. S., and Rebrova, O. I.</AU>
<TI>Experience in copaxon treatment in Russia</TI>
<SO>Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova / Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov.</SO>
<YR>2005</YR>
<VL>105</VL>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zavalishin-2006" MODIFIED="2009-07-22 17:27:05 +0200" MODIFIED_BY="[Empty name]" NAME="Zavalishin 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 17:27:05 +0200" MODIFIED_BY="[Empty name]" NOTES="RUSSIAN" NOTES_MODIFIED="2009-07-22 17:27:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zavalishin IA, Peresedova AV, Stoida NI, Rebrova O, Zakharova MN, Adarcheva LS, et al</AU>
<TI>[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis]</TI>
<SO>Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova / Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov.</SO>
<YR>2006</YR>
<VL>Spec No 3</VL>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziemssen-2008" MODIFIED="2009-07-22 17:07:06 +0200" MODIFIED_BY="[Empty name]" NAME="Ziemssen 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-22 17:07:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziemssen T, Hoffman J, Apfel R, Kern S </AU>
<TI>Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis</TI>
<SO>Health and quality of life outcomes</SO>
<YR>2008</YR>
<VL>6</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-02 23:01:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE=""/>
<IDENTIFIER MODIFIED="2009-06-02 23:01:47 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwibel-2006" MODIFIED="2009-07-22 17:07:31 +0200" MODIFIED_BY="[Empty name]" NAME="Zwibel 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 17:07:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwibel HL</AU>
<TI>Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>378-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-09-19 15:13:41 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-11-05 12:10:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Comi-2008" MODIFIED="2009-11-05 12:10:05 +0100" MODIFIED_BY="[Empty name]" NAME="Comi 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-04 12:53:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Comi G, Carrà A, Fazekas F, Rieckmann P, Bajenaru O, Hillert J et al</AU>
<TI>Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome: subgroup analysis</TI>
<SO>Multiple Sclerosis/ World Congress on treatment and Research in Multiple Sclerosis Montreal 2008</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>suppl 1</NO>
<PG>S38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 12:52:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comi G</AU>
<TI>PreCISe study Group. early glatiramer acetate treatment in delaying conversion to clinically definite multiple sclerosis (CDMS) in subjects presenting with a clinically isolated syndrome</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70 Suppl</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-05 12:10:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tintore Mar</AU>
<TI>New options for early treatment of multiple sclerosis</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>2009</YR>
<VL>277</VL>
<NO>S1</NO>
<PG>S9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-04-14 11:18:47 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-04-14 11:18:47 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Boneschi-2003" MODIFIED="2009-11-02 20:21:56 +0100" MODIFIED_BY="Deirdre M Beecher" NAME="Boneschi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsy JS, Ladkani D et al</AU>
<TI>Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials</TI>
<SO>Multiple Sclerosis</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brocke-1996" MODIFIED="2009-11-02 20:22:15 +0100" MODIFIED_BY="Deirdre M Beecher" NAME="Brocke 1996" TYPE="JOURNAL_ARTICLE">
<AU>Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T et al</AU>
<TI>Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein</TI>
<SO>Nature</SO>
<YR>1996</YR>
<VL>379</VL>
<NO>6563</NO>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caramanos-2005" MODIFIED="2009-07-22 18:28:52 +0200" MODIFIED_BY="[Empty name]" NAME="Caramanos 2005" TYPE="JOURNAL_ARTICLE">
<AU>Caramanos Z, Arnold DL</AU>
<TI>Evidence for use of glatiramer acetate in multiple sclerosis</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>2</NO>
<PG>74-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Comi-2005" MODIFIED="2009-07-22 18:29:00 +0200" MODIFIED_BY="[Empty name]" NAME="Comi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Comi G, Hartung HP, Boneschi FM</AU>
<TI>Evidence for use of glatiramer acetate in multiple sclerosis</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>2</NO>
<PG>75-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drago-1999" MODIFIED="2009-07-22 18:29:12 +0200" MODIFIED_BY="[Empty name]" NAME="Drago 1999" TYPE="JOURNAL_ARTICLE">
<AU>Drago F, Brusati C, Mancardi GL, Murialdo A, Rebora A</AU>
<TI>Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis (letter)</TI>
<SO>Archives of Dermatology</SO>
<YR>1999</YR>
<VL>135</VL>
<NO>10</NO>
<PG>1277-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebers-2008" MODIFIED="2009-10-21 22:56:31 +0200" MODIFIED_BY="[Empty name]" NAME="Ebers 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH</AU>
<TI>Disability as an outcome in MS clinical trials</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>71</VL>
<PG>624-631</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edgar-2004" MODIFIED="2009-07-22 18:29:34 +0200" MODIFIED_BY="[Empty name]" NAME="Edgar 2004" TYPE="JOURNAL_ARTICLE">
<AU>Edgar CM, Brunet DG, Fenton P, McBride EV, Green P</AU>
<TI>Lipoatrophy in patients with multiple sclerosis on glatiramer acetate</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>1</NO>
<PG>58-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ge-2000" MODIFIED="2009-07-22 18:29:44 +0200" MODIFIED_BY="[Empty name]" NAME="Ge 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarono F et al</AU>
<TI>Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>4</NO>
<PG>813-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-04-14 11:18:47 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for systematic Reviews of Interventions. Version 5.0.0(updated February 2008).The Cochrane Collaboration, 2008</TI>
<SO>www.cochrane-handbook. org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hwang-2001" NAME="Hwang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hwang L, Orengo I</AU>
<TI>Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis</TI>
<SO>Cutis</SO>
<YR>2001</YR>
<VL>68</VL>
<NO>4</NO>
<PG>287-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carroll D</AU>
<TI>Assessing the quality of randomised trials: is blinding necessary?</TI>
<SO>Controlled clinical trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" MODIFIED="2009-07-22 18:30:00 +0200" MODIFIED_BY="[Empty name]" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1444-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-11-10 12:07:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008.</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mancardi-2000" MODIFIED="2009-07-22 18:30:12 +0200" MODIFIED_BY="[Empty name]" NAME="Mancardi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, et al</AU>
<TI>Localized lipoatrophy after prolonged treatment with copolymer 1</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<NO>3</NO>
<PG>220-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McFarland-2008" MODIFIED="2009-11-10 09:52:38 +0100" MODIFIED_BY="[Empty name]" NAME="McFarland 2008" TYPE="JOURNAL_ARTICLE">
<AU>McFarland H F</AU>
<TI>Aletuzumab versus interferon beta-1a;implications for pathology and trial design</TI>
<SO>neurology</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>26-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munari-2004a" MODIFIED="2009-09-27 11:39:55 +0200" MODIFIED_BY="[Empty name]" NAME="Munari 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Munari LM, Filippini G</AU>
<TI>Lack of evidence for use of glatiramer acetate in multiple sclerosis</TI>
<SO>Lancet Neurology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>11</NO>
<PG>641</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munari-2005" MODIFIED="2009-09-27 11:41:17 +0200" MODIFIED_BY="[Empty name]" NAME="Munari 2005" TYPE="JOURNAL_ARTICLE">
<AU>Munari LM, Filippini G</AU>
<TI>Evidence for use of glatiramer acetate in multiple sclerosis (Authors' reply)</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>2</NO>
<PG>76-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" MODIFIED="2009-07-22 18:30:23 +0200" MODIFIED_BY="[Empty name]" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al</AU>
<TI>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prentice-1989" MODIFIED="2009-07-22 18:31:30 +0200" MODIFIED_BY="[Empty name]" NAME="Prentice 1989" TYPE="JOURNAL_ARTICLE">
<AU>Prentice RL</AU>
<TI>Surrogate endpoints in clinical trials: definition and operational criteria</TI>
<SO>Statistics in Medicine</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>4</NO>
<PG>431-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-04-14 11:04:05 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rio-2002" MODIFIED="2009-11-05 12:10:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rio 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rio J, Nos C, Tintorè M, Borras C, Galàn I, Comabella M, Montalban X</AU>
<TI>assessment of different treatment failure criteria in a Cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta:implications for clinical trials</TI>
<SO>Ann Neurol</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>400-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rio-2006" MODIFIED="2009-09-29 17:15:06 +0200" MODIFIED_BY="[Empty name]" NAME="Rio 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rio J, Nos C, Tintoré , èllez N, Galàn I, Pelayo R, Comabella M, Montalban X</AU>
<TI>Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients</TI>
<SO>Ann Neurol</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>344-352</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teitelbaum-1997" MODIFIED="2009-07-22 18:30:42 +0200" MODIFIED_BY="[Empty name]" NAME="Teitelbaum 1997" TYPE="JOURNAL_ARTICLE">
<AU>Teitelbaum D, Arnon R, Sela M</AU>
<TI>Coplymer 1: from basic research to clinical application</TI>
<SO>Cellular and Molecular Life Sciences: CMLS</SO>
<YR>1997</YR>
<VL>53</VL>
<NO>1</NO>
<PG>24-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wisniewski-1977" MODIFIED="2009-07-22 18:30:48 +0200" MODIFIED_BY="[Empty name]" NAME="Wisniewski 1977" TYPE="JOURNAL_ARTICLE">
<AU>Wisniewski HM, Keith AB</AU>
<TI>Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>2</NO>
<PG>144-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2009-07-22 18:30:54 +0200" MODIFIED_BY="[Empty name]" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J, Collins R, Sleight P</AU>
<TI>Beta-blockade during and after myocardial infarction: an overview of the randomised trials</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>5</NO>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-11-02 20:03:44 +0100" MODIFIED_BY="Deirdre M Beecher">
<REFERENCE ID="REF-Munari-2004" MODIFIED="2009-11-02 20:03:44 +0100" MODIFIED_BY="Deirdre M Beecher" NAME="Munari 2004" TYPE="COCHRANE_REVIEW">
<AU>Munari LM, Lovati R, Boiko A</AU>
<TI>Therapy with glatiramer acetate for multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-11-02 20:03:09 +0100" MODIFIED_BY="Deirdre M Beecher">
<IDENTIFIER MODIFIED="2009-11-02 20:03:09 +0100" MODIFIED_BY="Deirdre M Beecher" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD004678"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-09-14 16:12:16 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Rovaris-2007" MODIFIED="2009-07-22 18:33:41 +0200" MODIFIED_BY="[Empty name]" NAME="Rovaris 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E et al</AU>
<TI>Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial</TI>
<SO>Multiple sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>502-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sajja-2008" MODIFIED="2009-09-14 16:12:16 +0200" MODIFIED_BY="[Empty name]" NAME="Sajja 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sajja BR, Narayana PA, Wolinsky JS, Ahn CW</AU>
<TI>Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter stud</TI>
<SO>Multiple sclerosis</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-04-14 11:33:10 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-04-14 11:33:10 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-01-26 16:13:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bornstein-1987">
<CHAR_METHODS MODIFIED="2009-11-25 14:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>Design :Randomised controlled trial.<BR/>Enrollement :Patients have been enrolled in matched pairs with random assignment of either patient.<BR/>Intention-to-treat analysis.<BR/>Blindness: Double-blind, but patient's self-evaluation of either side effects or changes in neurologic status were reported to an unblinded clinical assistant.<BR/>Treatment duration: 24 months.<BR/>Follow-up duration: 24 months. </P>
<P>Withdrawn criteria of inclusion:: unusable data (2 placebo)<BR/>Dropouts = 7: placebo = 4 (2 psychological reason and 2 unstated) 17%, GA = 3 (1 exacerbation; 2 unstated) 12%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-13 12:22:43 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients: GA 25, placebo 25.<BR/>Israel 1 centre.<BR/>Sex: both.<BR/>Age: 20-35<BR/>Included (36%): definite MS with RR course, &gt;= 2 exacerbations in the 2 years before admission, Kurtzke &lt;= 6, emotionally stable. Patients enrolled when "clinically stable" and out of steroid treatment. Excluded (64%): age (23), low frequency of exacerbations (21), lack of documentation (19), psychologic profile (15), transition to chronic (8), distance from the clinic (3), pregnancy (1).<BR/>Baseline characteristics:<BR/>58% female<BR/>mean age: GA 30.0 yrs, placebo 31.1 yrs<BR/>mean EDSS: GA 2.9, placebo 3.2<BR/>disease duration: GA 4.9 yrs, placebo 6.1 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 16:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>Rx: GA * 20 mg.<BR/>Placebo: bacteriostatic saline<BR/>Subcutaneous GA or placebo self-administered daily<BR/>Co-interventions: unspecified steroid treatment during exacerbations; symptomatic medications (e.g.: cholinergic and spasmolytic drugs)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-13 12:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of relapse-free patients at the end of follow-up<BR/>Secondary outcomes: frequency of relapses, change in EDSS scores from baseline, time to progression<BR/>Relapse defined as: patient symptoms accompanied by observed objective changes on the neurologic exam involving an increase of at least 1 point in the score for 1 of the 8 functional group of Kurtzke scale. Sensory symptoms alone not considered<BR/>Progression defined as: increase of at least 1 point EDSS maintained for at least 3 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-13 12:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad score = 3<BR/>Two different preparations of Copolymer-1 have been used in the study, but patients treated with either preparation cannot be identified throughout the trial<BR/>Assumptions: 2 withdrawn in placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-26 16:12:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bornstein-1991">
<CHAR_METHODS MODIFIED="2010-01-13 12:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled study</P>
<P>Two center</P>
<P>Randomization within centers with two baseline EDSS strata (&lt; 5 and &gt; or equal 5)</P>
<P>Double blind</P>
<P>Treatment duration 24 months</P>
<P>Withdrawals 18.9% (10 GA-10 P) 6 for not consent , 5 for side effects and 3 for clinical worsening and 6 for various reasons</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 16:11:01 +0100" MODIFIED_BY="[Empty name]">
<P>51 GA and 55 Placebo.</P>
<P>Definte diagnosis of MS according to Poser criteria</P>
<P>Chronic progressive course for at least 18 months</P>
<P>no more than two exacerbation in the previous 2 years</P>
<P>20-60 years of age</P>
<P>2-6.5 EDSS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 16:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>GA * 20 mg or placebo (saline alone) self injected subcutaneously twice a day</P>
<P>Limited use of steroids was allowed during exacerbation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-14 10:57:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary:Confirmed progression (worsening of 1 EDSS or 1.5 according to basal EDSS ( 5 or less) maintained at 3 months</P>
<P>Secondary : time to progression, EDSS change</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-22 17:31:23 +0200" MODIFIED_BY="[Empty name]">
<P>The change from baseline in EDSS score over the study period was evaluated but the corresponding data were not reported in the paper but described in term of percentage of improved, stable or worse patients. This study was not included in the analysis for this outcome (see 4.4) </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-26 16:03:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comi-2001">
<CHAR_METHODS MODIFIED="2010-01-13 12:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>Double -blind</P>
<P>placebo controlled</P>
<P>Intention-to-treat analysis<BR/>
</P>
<P>Treatment period: 9 months<BR/>Follow-up period: 9 months<BR/>Drop-outs:</P>
<P>- GA = 7 (3 adverse events, 1 moved away from study center, 1 severe exacerbation, 4 withdrew consent; more than one causes are counted for the same patient) 6%</P>
<P>- Placebo = 7 (2 adverse events, 1 treatment believed ineffective, 1 poor compliance, 1 lost to follow-up, 2 refused to continue MRI monitoring) 6%<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 16:03:13 +0100" MODIFIED_BY="[Empty name]">
<P>239 patients: GA 119, placebo 120<BR/>Europe and Canada 29 centres<BR/>Sex: both.<BR/>Age: 18-50<BR/>Included (49%): definite MS with RR course, a diagnosis of MS for at least 1 year, age 18-50 inclusive, EDSS of 0 to 5, at least 1 documented relapse in the preceding 2 years, at least 1 enhancing lesion in their screening brain MRI, clinically relapse-free and steroids-free in the 30 days before entry<BR/>Excluded (51%): previous use of GA or oral myelin, prior lymphoid irradiation, use of immunosuppressant or cytotoxic agents in the past 2 years, use of azathioprine, cyclosporine, interferons, deoxyspergualin, chronic corticosteroids during the previous 6 months. Concomitant therapy with an experimental drug for MS or for another disease. Serious intercurrent systemic or psychiatric illnesses; unwilling to practice reliable contraception during study; known hypersensitivity to Gadolinium-DTPA or unavailable to undergo repeat MRI studies. Currently on relapse or steroid treatment (13) ; unspecified requirement unmet (233)<BR/>Baseline characteristics:<BR/>Unspecified gender distribution<BR/>mean age: GA 34.1, placebo 34.0<BR/>mean EDSS: GA 2.3 placebo 2.4<BR/>disease duration: GA 7.9 years, placebo 8.3 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 16:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>Rx: GA 20 mg.<BR/>Placebo: unspecified preparation<BR/>Subcutaneous GA or placebo self-administered daily.<BR/>Co-interventions: relapses could be treated by a standard dose of 1.0 g i.v. methylprednisolone for 3 consecutive days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-26 16:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: total number of enhancing lesions on MRI.<BR/>Secondary outcomes: total volume of enhancing lesions, number of new enhancing lesions, number of new lesions on T2-weighted images,percentage change of lesion volume on T2-weighted images, change in the volume of hypointense lesions on T1-weighted images.<BR/>Tertiary outcomes: relapse rate, number of relapses, proportion of relapse-free patients<BR/>Relapse defined as: appearance or reappearance of one or more neurologic symptoms, accompanied by abnormalities persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurologic state of at least 30 days. A relapse was confirmed when patient&#8217;s symptoms were accompanied by objective changes in neurologic examination consistent with at least 0.5 EDSS increase, 1 grade in the score of two or more functional systems, or 2 grades in one functional system. Transient neurologic deterioration associated with fever or infection in MS patients was not considered as relapse, nor was a change in bowel, bladder or cognitive function alone.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-13 12:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad score = 4<BR/>The Authors state that physician blinding was not formally assessed because primary and secondary outcome measures were MRI patterns. Nevertheless, both the treating neurologist and the patient were informed of the importance of not discussing safety issues with the examining neurologist</P>
<P>The change from baseline in EDSS score over the study period was evaluated but the corresponding data (mean +/-SD) were not reported in the paper. This study was not included in the analysis for this outcome (see 1.1)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-26 16:04:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filippi-2006">
<CHAR_METHODS MODIFIED="2010-01-13 12:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>Design of the study :Randomised controlled trial<BR/>Allocation: Central allocation at trial office list 1:1:1<BR/>158 participating clinical centers worldwide</P>
<P>Blindness: double blind<BR/>Treatment duration 14 months</P>
<P>Intention-to-treat analysis</P>
<P>Withdrawals 37-7% (50 mg) 41 -7% (5 mg) 42 -7%(placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 16:04:01 +0100" MODIFIED_BY="[Empty name]">
<P>1651 patients randomized, 7 were excluded and 1644 were treated : 543 ( 50 mg) 553 (5 mg) 548 placebo</P>
<P>Inclusion criteria clinically definite MS, relapsing-remitting course, Disease duration at least 6 months, age 18-50, EDSS 0-5.0, one year pre study relapse frequency 1.0, lack of steroid in the last one month before entry, birth control when appropriate</P>
<P>relapse defined as occurrence or reappearance of a new or more symptoms accompanied by a change od at least 0.5 EDSS or one or more grade in at least two functional systems</P>
<P>Exclusion:previous use of cladribine, oral myelin or total irradiation, immunoglobulins, instable significant clinical conditions ,gadolinium sensitivity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-10 09:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>Enteric -coated tablets containing 50 or 5 mg of glatiramer acetate or placebo (unspecified)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-13 12:27:28 +0100" MODIFIED_BY="[Empty name]">
<P>primary outcome the total number of confirmed relapses observed during the study period</P>
<P>Secondary</P>
<P>clinical: number of relapses treated with corticosteroids, are under curve of the EDSS change</P>
<P>MRI (cohort of 486 patients) number and volume of GAD+lesions,number of new T2 lesions</P>
<P>Tertiary outcomes. EDSS changes, proportion of patients relapse free, time to second relapse, number of relapse requiring hospitalisation</P>
<P>MRI number and volume of hypointense lesions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-23 15:01:02 +0200" MODIFIED_BY="[Empty name]">
<P>Jadad score =5</P>
<P>A descriptive analysis of the study was made because the published data were not consistent with the required parameters of treatment effect (see 1.5)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-26 16:05:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1995">
<CHAR_METHODS MODIFIED="2010-01-13 12:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>Central allocation at trial office<BR/>Intention-to-treat analysis<BR/>Blindness :Double-blind<BR/>Treatment period: 24 months (+ 11 in the extension phase)<BR/>Follow-up period: 24 months (+ 11 in the extension phase)<BR/>Withdrawals: GA = 19 (3 pregnancy, 1 progression, 2 serious adverse event, 3 transient self-limited systemic reactions, 10 not specified) 15%<BR/>placebo = 17 (2 poor protocol compliance, 1transient self-limited reaction, 14 not specified). Nine additional patients (GA= 2, placebo= 7) dropped out during the extension study 13.5%<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-13 12:28:49 +0100" MODIFIED_BY="[Empty name]">
<P>251 patients: GA 125, placebo 126<BR/>USA 11 centres<BR/>Sex: both.<BR/>Age: 18-45<BR/>Included (88%): criteria clinically definite MS or laboratory-supported definite with RR course, ambulatory, with an EDSS of 0.0 to 5.0, a history of at least 2 clearly defined and documented relapses in the 2 years prior to entry, onset of the first relapse at least 1 year before randomisation, neurologically stable and free from corticosteroid therapy for at least 30 days prior to entry<BR/>Excluded (12%): treatment with GA or previous immunosuppression with cytotoxic therapy or lymphoid irradiation; pregnancy or lactation, IDDM, positive HIV/HTLV-1 serology, Lyme disease, required use of aspirin or chronic NSAID during trial; unwilling to undergo adequate contraception<BR/>Baseline characteristics:<BR/>73% female<BR/>mean age: GA 34.6 yrs, placebo 34.3 yrs<BR/>mean EDSS: GA 2.8, placebo 2.4<BR/>disease duration: GA 7.3 yrs, placebo 6.6 yrs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 16:05:35 +0100" MODIFIED_BY="[Empty name]">
<P>Rx: GA 20 mg.<BR/>Placebo: not specified.<BR/>Subcutaneous GA or placebo self-administered daily<BR/>Co-interventions: standard steroid protocol during exacerbations; conventional medication received at the time of randomisation<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: mean number of relapses. Secondary endpoints: proportion of relapse-free patients, time to first relapse after randomisation, proportion of patients with sustained disease progression and mean change in EDSS score. Relapse defined as: appearance or reappearance of one or more neurologic abnormalities persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurologic state of at least 30 days. A relapse was confirmed when patient&#8217;s symptoms were accompanied by objective changes in neurologic examination consistent with at least 0.5 EDSS increase, 2 points on one of the seven functional systems, or 1 point on two or more of the functional systems<BR/>Progression defined as: increase of at least 1 point EDSS maintained for at least 3 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-13 12:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad score = 5<BR/>Authors carried out both an intention-to treat and an on-treatment analyses, claiming that results are comparable<BR/>This study has been extended for an additional 11 months until all 203 remaining patients (i.e.: excluding 36 already withdrawn and 12 who refused to participate in the extension trial), have received 24 months of treatment. Clinical status of these 12 withdrawn between the early and the extension phase are no different from the remaining cohort. Extension study was carried out double blind. After this period a cohort of patients participate in the open label phase until 10 years (see text)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-26 16:06:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolinsky-2007">
<CHAR_METHODS MODIFIED="2009-11-25 15:49:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised Placebo- controlled study<BR/>Allocation: 2:1<BR/>Multinational multicenter</P>
<P>Blindness: double-blind<BR/>Treatment duration 3 years</P>
<P>Follow-up duration and blinded extension until the completion of the last included patient (4 years and 5 months)</P>
<P>Intention-to-treat analysis</P>
<P>interim treatment analysis . 2 planned</P>
<P>Assessment : treating and blind examining neurologist</P>
<P>Discontinuation: 197 patients 21%</P>
<P>Lost at follow-up GA 18 (2.9%) 9 Plac 7 (2.2%)</P>
<P>Drop out GA 170 (27%) ; Plac 91 (29%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-13 12:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>943 randomized , 627 GA and 316 Placebo</P>
<P>eligibility criteria :</P>
<P>Age: 30-65</P>
<P>EDSS 3.0-6.5</P>
<P>Progressive course from at least 6 months with objective evidence of functional piramidal dysfunction ( <U>&gt;</U> 2) and of disseminated involvement of the CNS by clinical MRI or evoked potentials and CSF abnormalities<BR/>Excluded patients with history of any relapse, spondylitic myelopathy and other progressive neurological disorders, previous immunosuppressive or immunomodulating therapy within 3 months, pregnancy or lactation, lymphopenia and allergy to gadolinium<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 16:06:08 +0100" MODIFIED_BY="[Empty name]">
<P>Therapy: GA 20 mg<BR/>Placebo: unspecified preparation<BR/>Subcutaneous GA or placebo self-administered daily.<BR/>Co-interventions with corticosteroid discouraged and limited to i.v. methylprednisolone for 5 consecutive days</P>
<P>concomitant treatment with immunosuppressive, immunomodulating not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-13 12:30:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of patients with sustained at 3 months disease progression of at least 1 EDSS (basal score 3 - 5) and 0.5 (basal score 5.5-6.5 )</P>
<P>Secondary outcome :</P>
<P>Clinical : proportion of progression free patients , mean change in EDSS score. and mean MSFC scores</P>
<P>MRI: change in cerebral flair lesion volume and number, number of Gd -enhancing lesions, volume of black holes as percentage of FLAIR -defined lesion burden and brain volume loss</P>
<P>Safety : adverse event reporting, vital signs ECG and laboratory tests<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-13 12:31:01 +0100" MODIFIED_BY="[Empty name]">
<P>Data safety monitoring board recommended early study termination ( November 2002, 3 years after study onset at July ,1999) for futility analysis</P>
<P>Posthoc sensitivity analysis was made</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>GA * prepared and supplied by Weinzmann Institute of Science and Bio-Yeda Co. (Rehovot, Israel); GA prepared and supplied by TEVA Pharmaceutical Industries, Ltd., Petah Tiqva, Israel)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-11-10 10:20:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abramsky-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled open-label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:55:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Achiron-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (Cancer risk) during GA and IFN therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:55:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnold-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:55:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized comparative trial in RR MS evaluating GA (20 mg/d SC) after the last of 3 monthly mitoxantrone infusions (36 mg/m2 total), or GA alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:55:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ball-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:55:37 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE Panniculitis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baumhefner-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled open-label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:55:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blanco-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:55:52 +0100" MODIFIED_BY="[Empty name]">
<P>Observational clinic-immunological study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 19:00:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boiko-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 19:00:57 +0200" MODIFIED_BY="[Empty name]">
<P>Longitudinal not randomized study not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bornstein-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled open-label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosca-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (Necrotising cutaneous) in a patients treated with GA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brenner-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Experimental series. Only laboratory measures of treatment effect are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:56:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brochet-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:56:26 +0100" MODIFIED_BY="[Empty name]">
<P>Re-analysis of long term open label study until 10 years of Johnson's RCT 1995.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:56:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cadavid-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized CTof IFNbeta-1b versus GA on MRI -clinical activity in RR MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:57:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caon-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:57:04 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical not randomized not controlled study (GA after IFN therapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:57:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capobianco-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:57:28 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical not randomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:57:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carra-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective longitudinal observational comparative not randomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castelli_x002d_Haley-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:03 +0100" MODIFIED_BY="[Empty name]">
<P>Comparative (GA vs IFN 1a) not randomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Charach-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:06 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE Crohn's disease) in a patient with multiple sclerosis treated with copaxone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:19:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:19:16 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental series from subset of the US copaxone phase III core study. Only laboratory measures of treatment effect are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cicek-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE urticarial vasculitis) in a patient GA treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report from a subset of the US copaxone phase III core study where only MRI parameters are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Constantinescu-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open-label controlled trial. Only laboratory measures of treatment effect are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daugherty-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:29 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical not randomized study of patients treated with immunomodulating agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Seze-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report from a phase I uncontrolled trial of oral copaxone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Stefano-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study evaluating the efficacy of GA and Methylprednisolone followed by GA alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:58:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Stefano-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:58:55 +0100" MODIFIED_BY="[Empty name]">
<P>Open label studies evaluating protiramer a high molecular weight synthetic copolymer mixture in RR MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:59:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Debouverie-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:59:02 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:59:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical study of patients treated with immunomodulating agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duda-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Farina-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised open-label controlled trial. Only laboratory measures of treatment effect are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:59:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feigin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE cancer ) in MS patients treated with GA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:59:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiore-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>Observational v study on GA focused on side effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Flechter-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label trial comparing two Copaxone administration schedules and interferon-beta1b.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Flechter-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report from an open-label uncontrolled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:59:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ford-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:59:41 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective open-label study ;extension at 10 years of Johnson 1995 trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-19 23:33:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fusco-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-19 23:33:32 +0200" MODIFIED_BY="[Empty name]">
<P>Non-randomised study evaluating copaxone in relapsing-remitting MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 09:59:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gajofatto-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 09:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Observational open label study evaluating switching first-line disease-modifying therapy after failure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:19:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Barragan-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:19:44 +0100" MODIFIED_BY="[Empty name]">
<P>Observational clinic- immunological study evaluating immunomodulating agents,</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:00:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghezzi--b-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study evaluating immunomodulating agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:00:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghezzi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:00:24 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study evaluating immunomodulating agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:00:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>RCT evaluating the efficacy of GA and natalizumab versus GA alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:00:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haas-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:00:38 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective and open-label clinical study of first line immunomodulating therapies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:00:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harde-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:00:47 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE Embolia cutis medicamentosa ) in a MS patient treated with GA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:00:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>Extension study open label of Johnson 1995 at 6 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:01:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:01:01 +0100" MODIFIED_BY="[Empty name]">
<P>Extension at 6 years open label of Johnson 1995 study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:01:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>Extension of Johnson 's study 1995 Patients treated with GA after 36 months of RCT study (open label extension phase at 8 years).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-11 15:45:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jolly-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-11 15:45:04 +0200" MODIFIED_BY="[Empty name]">
<P>RCT crossover open -label on Impact of warm compresses on local injection-site reactions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karandikar-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Experimental series. Only laboratory measures of treatment effect are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised, open-label study comparing interferon-beta1a, interferon-beta1b and copaxone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:01:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled not randomized study evaluating MRI (spectroscopy) outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:01:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-khan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study evaluating MRI outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 18:57:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kott-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 18:57:31 +0200" MODIFIED_BY="[Empty name]">
<P>Open-label uncontrolled study of copaxone in MS patients with or without optic neuritis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Mantia-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:02 +0100" MODIFIED_BY="[Empty name]">
<P>Comparative study evaluating headache in MS patients treated with IFN vs Ga or azathioprine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lage-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:08 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study (outcome time missed from work).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Page-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:16 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study in patients treated with mitoxantrone(induction) followed by immunomodulating agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madray-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:20 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE Lymphoma ) in 1 patients treated with GA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mancardi-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report from an open study on copaxone where pretreatment data served as controls of treatment effect. Only MRI parameters are reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meiner-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Phase III uncontrolled open-label trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mesaros_x002c_-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:30 +0100" MODIFIED_BY="[Empty name]">
<P>MR study of placebo group of Filippi 'trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mikol-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT open label comparing IFN1 a vs GA in RR.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Milanese-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:39 +0100" MODIFIED_BY="[Empty name]">
<P>Observational post-marketing study in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report from a non-randomised open study on copaxone where pretreatment data served as controls of treatment effect.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:45 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study in Buffalo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:02:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:02:49 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled open label study GA (follow-up 22 years).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:03 +0100" MODIFIED_BY="[Empty name]">
<P>Safety ( AE hepatitis) in a GA treated MS patient.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nolden-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>Safety ( AE depression) in GA treated MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ollendorf-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:20 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study on co-prescription in GA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Orlova-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:25 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled clinical-immunological study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patten-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:32 +0100" MODIFIED_BY="[Empty name]">
<P>Safety ( AE depression) in GA treated MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-P_x00f6_llmann-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:43 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (AE headache) in GA treated MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-20 15:57:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-20 15:57:02 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental series comparing the effect of copaxone on MS patients and healthy volunteers on laboratory immunological measures of treatment effect.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:03:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramtahal-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:03:51 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study not controlled after mitoxantrone therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:04:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rauschka-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:04:28 +0100" MODIFIED_BY="[Empty name]">
<P>safety (AE anaphylaxis) in a patient GA treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-08 16:02:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rio-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-08 16:02:08 +0200" MODIFIED_BY="[Empty name]">
<P>observational study evaluating reasons for treatment discontinuation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:04:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rovaris-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>Review of MRI effects of GA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:04:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rovaris-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:04:49 +0100" MODIFIED_BY="[Empty name]">
<P>Extension of Comi's study 2001 at 5.8 years. Open label phase after RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:04:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwid-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:04:56 +0100" MODIFIED_BY="[Empty name]">
<P>Extensions study of Johnson 1995:open label follow-up at 10 year of GA treatment (cognitive function).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shipova-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:03 +0100" MODIFIED_BY="[Empty name]">
<P>MRI (Spinal cord)observational study during immunomodulatory treatment (GA IFN).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sidoti-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:12 +0100" MODIFIED_BY="[Empty name]">
<P>Case report (GA in psychosis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sindic-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study in Belgium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soares-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (Adverse events -panniculitis-) in patients GA-treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sormani-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Re-analysis of the European-Canadian MRI study aimed at validating MRI endpoints as surrogates of clinical outcomes in MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sormani-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:38 +0100" MODIFIED_BY="[Empty name]">
<P>Additional trial analysis (Comi 2001) focused on MRI measures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sormani-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:47 +0100" MODIFIED_BY="[Empty name]">
<P>Additional trial analysis (Comi 2001) focused on MRI/clinical measures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:05:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Then_x002c_-Bergh-F-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:05:57 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (Adverse events -leukemia -) in a patient GA-treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:06:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thouvenot-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:06:10 +0100" MODIFIED_BY="[Empty name]">
<P>Safety (Adverse event -erithema nodoso -) in a patient GA-treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:06:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tilbery-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:06:18 +0100" MODIFIED_BY="[Empty name]">
<P>Post marketing study at a Barzilian center.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:06:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Torkildsen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study in Norway.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:06:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tremlett-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:06:53 +0100" MODIFIED_BY="[Empty name]">
<P>Safety study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:06:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Twork-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:06:52 +0100" MODIFIED_BY="[Empty name]">
<P>Post marketing study on tolerability of GA and IFN treatment in MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:20:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valenzuela-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:20:19 +0100" MODIFIED_BY="[Empty name]">
<P>observational not controlled clinic- immunological study on GA therapy in MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:07:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vallittu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>Observational not controlled study of GA efficacy in IFN intolerant MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:07:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vollmer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:07:09 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparative evaluating GA treated MS patients after or without previous induction with mitoxantrone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:07:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weder-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:07:17 +0100" MODIFIED_BY="[Empty name]">
<P>observational not randomised clinical immunological study on GA treated vs untreated RR MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:07:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinstein-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:07:23 +0100" MODIFIED_BY="[Empty name]">
<P>RCT evaluating cognitive function In GA vs placebo: Baseline test performance was normal and improved over time in both treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-20 16:30:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolinsky-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-20 16:30:00 +0200" MODIFIED_BY="[Empty name]">
<P>Extension study of the US copaxone phase III core study evaluating clinical- MRI parameters.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 18:59:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wynn-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 18:59:00 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter, randomized, double-blind study comparing the safety and efficacy of two GA doses: 20mg/day, the currently approved dose, versus 40 mg/day.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ytterberg-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>observational comparative study in patients treated with copaxone and IFNbeta versus copaxone alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:07:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zavalishin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:07:44 +0100" MODIFIED_BY="[Empty name]">
<P>Open label observational study in Russia.<BR/>
<BR/>
<BR/>
<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:20:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zavalishin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:20:26 +0100" MODIFIED_BY="[Empty name]">
<P>Comparative not randomized study evaluating copaxone versus Rebif 22 Russian.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-10 10:08:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziemssen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-10 10:08:00 +0100" MODIFIED_BY="[Empty name]">
<P>uncontrolled open-label study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-02 22:52:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zwibel-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-02 22:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>open-label not randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-09-19 15:13:41 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-01-26 16:14:37 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-01-26 16:14:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comi-2008">
<CHAR_STUDY_NAME MODIFIED="2009-11-04 12:54:36 +0100" MODIFIED_BY="[Empty name]">
<P>PreCISe </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-11-10 10:08:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, prospective , double-blind, placebo controlled multinational trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 11:25:39 +0100" MODIFIED_BY="[Empty name]">
<P>481 patients presenting with a clinically isolated syndrome (CIS) suggestive of MS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-26 16:14:14 +0100" MODIFIED_BY="[Empty name]">
<P>GA sc 20 mg qd or placebo for three years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-10 10:08:25 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was time to clinically definite MS, based on a second clinical attack</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-11-05 11:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>January 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-26 16:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Prof G Comi, Institute of Experimental Neurology, Department of Neurology University Vita-Salute</P>
<P>Scientific Institute S Raffaele, Milan, Italy</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-04-14 11:33:10 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-01-26 16:06:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:01:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bornstein-1987">
<DESCRIPTION>
<P>Quote "the random assignment of the first patient of a pair determined the assignment of both " pg 409</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:02:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1991">
<DESCRIPTION>
<P>quote" by randomized block design with two baseline EDSS strata &lt; 5.0 and 5.0 or greater" </P>
<P>pg 534</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 12:26:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comi-2001">
<DESCRIPTION>
<P>The randomization list, stratified by centers, was central computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:04:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filippi-2006">
<DESCRIPTION>
<P>Quote:" Randomization list , stratified by centers, was central computer generated by Teva " pg 214</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:05:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1995">
<DESCRIPTION>
<P>Quote " a centralized randomization scheme was used " pg 1270</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:06:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolinsky-2007">
<DESCRIPTION>
<P>Quote "randomized" pg 15</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-01-26 16:02:08 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 15:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bornstein-1987">
<DESCRIPTION>
<P>see above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:02:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1991">
<DESCRIPTION>
<P>quote " the investigator notified the statistical center , which assigned a randomization code number " pg 534</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-27 08:26:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comi-2001">
<DESCRIPTION>
<P>see above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:28:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filippi-2006">
<DESCRIPTION>
<P>see above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-18 16:09:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 12:13:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolinsky-2007">
<DESCRIPTION>
<P>see above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-01-26 16:06:36 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-26 16:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1987">
<DESCRIPTION>
<P>Quote pg 409: "A neurologist unaware of the patient's treatment group completed a neurologic examination and status evaluation. The patient's self evaluation of (...) side effects were reported to the clinical assistant, who was not blinded to the treatment." However the trial failed to carry out a fully blind assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-26 16:02:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1991">
<DESCRIPTION>
<P>Quote pg 534 "the side effects were not discussed with the neurologist. Another blinded neurologist was available to examine patients with severe or unusual side effects"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-26 16:03:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comi-2001">
<DESCRIPTION>
<P>All personnel were unaware of treatment allocation, patient and physician blinding was not formally assessed as outcome measures focused on MRI parameters.Quote " both the treating neurologist and the patient were informed on the importance of not discussing safety issue with the examining neurologist " pg 291</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-26 16:05:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filippi-2006">
<DESCRIPTION>
<P>Quote " all personnel involved in the study were unaware of the treatment allocation. both the treating neurologist and the patient were informed on the importance of not discussing safety issue with the examining neurologist " pg 214</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-26 16:05:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1995">
<DESCRIPTION>
<P>quote "nurse coordinator and neurologists were blinded "</P>
<P>pg 1270</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-26 16:06:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolinsky-2007">
<DESCRIPTION>
<P>Quote pg 16 "All patients were attended by a treating neurologist and examining neurologist who were blinding to treatment"</P>
<P>No further information were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-01-26 16:02:36 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-26 16:01:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1987">
<DESCRIPTION>
<P>Withdrawn criteria of inclusion: unusable data (2 placebo)<BR/>Dropouts = 7: placebo = 4 (2 psychological reason and 2 unstated) 17%,</P>
<P>GA = 3 (1 exacerbation; 2 unstated) 12%.</P>
<P>Quote pg 410 "the partial data obtained from the other five patients were included in the analyses"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-26 16:02:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1991">
<DESCRIPTION>
<P>The 20 withdrawals had been considered in the statistical analyses pg 536</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-13 12:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comi-2001">
<DESCRIPTION>
<P>Only 6% drop-out for each group</P>
<P>- GA = 7 (3 adverse events, 1 moved away from study center, 1 severe exacerbation, 4 withdrew consent; more than one causes are counted for the same patient)</P>
<P>- Placebo = 7 (2 adverse events, 1 treatment believed ineffective, 1 poor compliance, 1 lost to follow-up, 2 refused to continue MRI monitoring)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-13 12:27:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filippi-2006">
<DESCRIPTION>
<P>Only 7% withdrawal for each group</P>
<P>Withdrawals 37 (50 mg); 41 (5 mg); 42 (placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-13 12:29:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1995">
<DESCRIPTION>
<P>Withdrawals: GA = 19 (3 pregnancy, 1 progression, 2 serious adverse event, 3 transient self-limited systemic reactions, 10 not specified) 15%<BR/>placebo = 17 (2 poor protocol compliance, 1transient self-limited reaction, 14 not specified). Nine additional patients (GA= 2, placebo= 7) dropped out during the extension study 13.5%.</P>
<P>They were included in the statistical analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-25 15:53:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolinsky-2007">
<DESCRIPTION>
<P>Discontinuation: 197 patients 21%</P>
<P>Lost at follow-up GA 18 (2.9%) 9 Plac 7 (2.2%)</P>
<P>Drop out GA 170 (27%) ; Plac 91 (29%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-04-14 11:33:10 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 14:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:26:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 16:05:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filippi-2006">
<DESCRIPTION>
<P>Some secondary and tertiary clinical outcomes data were un showed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-14 11:33:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolinsky-2007">
<DESCRIPTION>
<P>results are mentioned but not reported adequated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-01-13 12:31:29 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 14:59:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:11:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bornstein-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:26:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 12:28:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Filippi-2006">
<DESCRIPTION>
<P>Standard Deviation of results was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-25 15:47:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 12:31:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolinsky-2007">
<DESCRIPTION>
<P>Data safety monitoring board recommended early study termination (November 2002, 3 years after study onset at July ,1999) for futility analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-01-27 07:48:05 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-01-27 07:48:05 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-01-27 07:48:05 +0100" MODIFIED_BY="Grade Profiler">Glatiramer acetate versus placebo in relapsing remitting patient for multiple sclerosis</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Glatiramer acetate versus placebo in relapsing remitting patient for multiple sclerosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with multiple sclerosis<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Glatiramer acetate versus placebo in relapsing remitting patient<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Glatiramer acetate versus placebo in relapsing remitting patient</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Patients who progressed - at 2 years</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.51 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>299<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>282 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>212 per 1000</B>
<BR/>(144 to 316)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>362 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>272 per 1000</B>
<BR/>(185 to 405)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Patients who progressed - at 35 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.81 </B>
<BR/>(0.5 to 1.29)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>203<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>233 per 1000</B>
<BR/>(144 to 372)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>289 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>234 per 1000</B>
<BR/>(144 to 373)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in disability score at the end of follow-up - at 2 years of follow-up</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Change in disability score at the end of follow-up - at 2 years of follow-up in the intervention groups was<BR/>
<B>0.33 lower</B>
<BR/>(0.58 to 0.08 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>301<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in disability score at the end of follow-up - at 35 months of follow-up</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Change in disability score at the end of follow-up - at 35 months of follow-up in the intervention groups was<BR/>
<B>0.45 lower</B>
<BR/>(0.77 to 0.13 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>203<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mean number of relapses - within 1 year of follow-up</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mean number of relapses - within 1 year of follow-up in the intervention groups was<BR/>
<B>0.35 lower</B>
<BR/>(0.53 to 0.16 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>287<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mean number of relapses - at 2 years of follow-up</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mean number of relapses - at 2 years of follow-up in the intervention groups was<BR/>
<B>0.51 lower</B>
<BR/>(0.81 to 0.22 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>298<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-03-05 16:01:07 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-12-20 17:27:00 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-11-10 10:23:43 +0100" MODIFIED_BY="[Empty name]">Jadad score</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD>
<P>Study</P>
</TD>
<TD>
<P>Bornstein 87</P>
</TD>
<TD>
<P>Johnson</P>
</TD>
<TD>
<P>Comi</P>
</TD>
<TD>
<P>Filippi</P>
</TD>
<TD>
<P>Bornstein 91</P>
</TD>
<TD>
<P>Wolinsky</P>
</TD>
</TR>
<TR>
<TD>
<P>Was the study described as randomized?</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Was the study described as double blind?</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Was there a description of withdrawals and dropouts?</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Appropriate randomization +/-</P>
</TD>
<TD>
<P>-1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-1</P>
</TD>
</TR>
<TR>
<TD>
<P>Appropriate</P>
<P>Blinding+/-</P>
</TD>
<TD>
<P>-1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-1</P>
</TD>
</TR>
<TR>
<TD>
<P>Score</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-01-26 16:21:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-11-05 11:57:59 +0100" MODIFIED_BY="[Empty name]">Included studies .RR patients. Clinical characteristics</TITLE>
<TABLE COLS="10" ROWS="8">
<TR>
<TD>
<P>Study</P>
</TD>
<TD COLSPAN="2">
<P>Bornstein 1987</P>
</TD>
<TD COLSPAN="2">
<P>Johnson 1995</P>
</TD>
<TD COLSPAN="2">
<P>Comi 2001</P>
</TD>
<TD COLSPAN="3">
<P>Filippi 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>Allocation (GA/Placebo)</P>
</TD>
<TD>
<P>GA</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>GA</P>
</TD>
<TD>
<P>placebo</P>
</TD>
<TD>
<P>GA</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>GA 50 mg</P>
</TD>
<TD>
<P>GA 5 mg</P>
</TD>
<TD>
<P>placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>N°</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>125</P>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>543</P>
</TD>
<TD>
<P>553</P>
</TD>
<TD>
<P>548</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex ( % Males)</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>23.8</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>Mean age</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>31.1</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>34.1+7.4</P>
</TD>
<TD>
<P>34+7.5</P>
</TD>
<TD>
<P>36.8-7.3</P>
</TD>
<TD>
<P>36.1-8</P>
</TD>
<TD>
<P>36.6-7.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Disease duration(years)</P>
</TD>
<TD>
<P>4,9</P>
</TD>
<TD>
<P>6.1</P>
</TD>
<TD>
<P>7.3+4.9</P>
</TD>
<TD>
<P>6.6+5.1</P>
</TD>
<TD>
<P>7.9+5.5</P>
</TD>
<TD>
<P>8.3+5,5</P>
</TD>
<TD>
<P>7.9+6.1</P>
</TD>
<TD>
<P>7.4-6.2</P>
</TD>
<TD>
<P>7.7-6.2</P>
</TD>
</TR>
<TR>
<TD>
<P>EDSS</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>2.8+1.2</P>
</TD>
<TD>
<P>2.4+1.3</P>
</TD>
<TD>
<P>2.3+1.1</P>
</TD>
<TD>
<P>2.4+1.2</P>
</TD>
<TD>
<P>2.3-1.1-</P>
</TD>
<TD>
<P>2.2-1.1</P>
</TD>
<TD>
<P>2.3-1.2</P>
</TD>
</TR>
<TR>
<TD>
<P>Pre 1 year RF</P>
</TD>
<TD>
<P>1.9</P>
</TD>
<TD>
<P>1.9</P>
</TD>
<TD>
<P>1.45</P>
</TD>
<TD>
<P>1.45</P>
</TD>
<TD>
<P>1.4</P>
</TD>
<TD>
<P>1.25</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-03-05 16:01:07 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-06-20 15:51:48 +0200" MODIFIED_BY="[Empty name]">Included studies: progressive patients Clinical characteristics</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TD>
<P>Study</P>
</TD>
<TD COLSPAN="2">
<P>Wolinsky2007</P>
</TD>
<TD COLSPAN="2">
<P>Bornstein 1991</P>
</TD>
</TR>
<TR>
<TD>
<P>Allocation(GA/Placebo)</P>
</TD>
<TD>
<P>GA</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>GA</P>
</TD>
<TD>
<P>placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>N°</P>
</TD>
<TD>
<P>627</P>
</TD>
<TD>
<P>316</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex (% Females)</P>
</TD>
<TD>
<P>47.2</P>
</TD>
<TD>
<P>51.9</P>
</TD>
<TD>
<P>54.9</P>
</TD>
<TD>
<P>54.5</P>
</TD>
</TR>
<TR>
<TD>
<P>Mean age</P>
</TD>
<TD>
<P>50.4+8.4</P>
</TD>
<TD>
<P>50.2+8.1</P>
</TD>
<TD>
<P>41.6</P>
</TD>
<TD>
<P>42.3</P>
</TD>
</TR>
<TR>
<TD>
<P>Disease duration</P>
</TD>
<TD>
<P>11+7.3</P>
</TD>
<TD>
<P>10.7+7.7</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>EDSS</P>
</TD>
<TD>
<P>4.9+1.2</P>
</TD>
<TD>
<P>4.9+1.2</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>5.5</P>
</TD>
</TR>
<TR>
<TD>
<P>Type of progression</P>
</TD>
<TD>
<P>PP</P>
</TD>
<TD>
<P>PP</P>
</TD>
<TD>
<P>PR?</P>
</TD>
<TD>
<P>PR?</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-03-05 16:23:49 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-11-02 12:54:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Glatiramer acetate versus placebo in relapsing remitting patient</NAME>
<DICH_OUTCOME CHI2="2.1523549462947598" CI_END="1.0497434132905015" CI_START="0.5717287168363839" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7747053986439131" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="72" I2="7.0785232964031355" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.02108315829872359" LOG_CI_START="-0.2428099934593978" LOG_EFFECT_SIZE="-0.11086341758033709" METHOD="MH" MODIFIED="2009-09-26 20:08:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34089633963160515" P_Q="0.0" P_Z="0.09960121132165035" Q="0.0" RANDOM="NO" SCALE="5.7" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="249" TOTAL_2="253" WEIGHT="200.0" Z="1.646790030077378">
<NAME>Patients who progressed</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1092199001811527" CI_END="1.1232961087429238" CI_START="0.5054413090363431" DF="1" EFFECT_SIZE="0.7534986766003334" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" I2="52.58910652634588" ID="CMP-001.01.01" LOG_CI_END="0.05049425442876483" LOG_CI_START="-0.2963292666634351" LOG_EFFECT_SIZE="-0.12291750611733514" MODIFIED="2009-09-26 20:08:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14641399523601795" P_Z="0.1647539433753306" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="149" WEIGHT="100.00000000000001" Z="1.389259207684555">
<NAME>at 2 years</NAME>
<DICH_DATA CI_END="1.021036507471418" CI_START="0.17127304633889062" EFFECT_SIZE="0.41818181818181815" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.009041270696049977" LOG_CI_START="-0.766310977649352" LOG_EFFECT_SIZE="-0.378634853476651" MODIFIED="2009-09-26 20:08:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.45544574873361776" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.2074308300395257" WEIGHT="27.06597392412509"/>
<DICH_DATA CI_END="1.380656765203259" CI_START="0.5582638156459386" EFFECT_SIZE="0.8779354838709678" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.14008572527982346" LOG_CI_START="-0.25316052041138126" LOG_EFFECT_SIZE="-0.05653739756577887" MODIFIED="2009-06-20 22:45:57 +0200" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.23099479131932418" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.05335859361665813" WEIGHT="72.93402607587493"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2864589869488048" CI_START="0.5042123823471925" DF="0" EFFECT_SIZE="0.8053872053872054" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.10939594520960569" LOG_CI_START="-0.29738649321128385" LOG_EFFECT_SIZE="-0.0939952740008391" MODIFIED="2009-09-13 19:32:47 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.36505322177247457" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="104" WEIGHT="100.0" Z="0.9057782950207033">
<NAME>at 35 months</NAME>
<DICH_DATA CI_END="1.2864589869488048" CI_START="0.5042123823471925" EFFECT_SIZE="0.8053872053872054" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.10939594520960569" LOG_CI_START="-0.29738649321128385" LOG_EFFECT_SIZE="-0.0939952740008391" MODIFIED="2009-09-13 19:32:47 +0200" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.23894601793397569" STUDY_ID="STD-Johnson-1995" TOTAL_1="99" TOTAL_2="104" VAR="0.05709519948650383" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.024985201474995" CI_END="-0.1788889369586005" CI_START="-0.5725647464965817" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.37572684172759113" ESTIMABLE="YES" I2="33.883974076144504" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2009-11-02 12:54:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2203600978059208" P_Q="0.5678173607735492" P_Z="1.8313959747693527E-4" Q="0.32634842657938723" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="249" TOTAL_2="255" UNITS="" WEIGHT="200.0" Z="3.741205631482988">
<NAME>Change in disability score at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6986367748956077" CI_END="-0.08268605692279599" CI_START="-0.580133511595465" DF="1" EFFECT_SIZE="-0.3314097842591305" ESTIMABLE="YES" I2="62.94425358378645" ID="CMP-001.02.01" MODIFIED="2009-11-02 12:54:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10043415527110588" P_Z="0.009013620766666097" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="151" WEIGHT="100.0" Z="2.6115370987253463">
<NAME>at 2 years of follow-up</NAME>
<CONT_DATA CI_END="-0.17247450005157117" CI_START="-1.7075254999484288" EFFECT_SIZE="-0.94" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.74" MODIFIED="2009-09-13 19:28:09 +0200" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="1.17" SD_2="1.57" SE="0.3916018386065111" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" WEIGHT="10.501438861636837"/>
<CONT_DATA CI_END="0.0029112625427820116" CI_START="-0.5229112625427821" EFFECT_SIZE="-0.26" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="0.21" ORDER="5" SD_1="1.13" SD_2="0.99" SE="0.13414086412637807" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" WEIGHT="89.49856113836316"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1417242902181923E-31" CI_END="-0.12800605516297114" CI_START="-0.7719939448370288" DF="0" EFFECT_SIZE="-0.44999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.02" MODIFIED="2009-11-02 12:54:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.006160170787575675" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="104" WEIGHT="99.99999999999999" Z="2.739131611587988">
<NAME>at 35 months of follow-up</NAME>
<CONT_DATA CI_END="-0.1280060551629712" CI_START="-0.7719939448370288" EFFECT_SIZE="-0.45" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="0.34" MODIFIED="2009-09-13 19:25:26 +0200" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="1.17" SD_2="1.17" SE="0.16428564370410678" STUDY_ID="STD-Johnson-1995" TOTAL_1="99" TOTAL_2="104" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.178536569507226" CI_END="1.5812017369008466" CI_START="1.1108315097246941" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3253107984849728" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="131" I2="44.278336381386126" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.19898728273015323" LOG_CI_START="0.045648190402556146" LOG_EFFECT_SIZE="0.1223177365663547" METHOD="MH" MODIFIED="2009-09-25 22:43:36 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.12674890452167709" P_Q="0.0" P_Z="0.0017665722741176963" Q="0.0" RANDOM="NO" SCALE="8.04" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="393" TOTAL_2="396" WEIGHT="300.0" Z="3.126904622968952">
<NAME>Patients relapse free</NAME>
<GROUP_LABEL_1>treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.3165992181033594" CI_END="1.6172862762644054" CI_START="1.020914534299032" DF="1" EFFECT_SIZE="1.284955666768582" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="65" I2="81.19098395465026" ID="CMP-001.03.01" LOG_CI_END="0.20878690129019714" LOG_CI_START="0.008989386713832098" LOG_EFFECT_SIZE="0.10888814400201463" MODIFIED="2009-09-25 22:43:17 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.021123258572278036" P_Z="0.03265242054676309" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="143" WEIGHT="100.0" Z="2.136331285600545">
<NAME>at 1 year</NAME>
<DICH_DATA CI_END="5.727533211800068" CI_START="1.3299966527135882" EFFECT_SIZE="2.76" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.7579676161782722" LOG_CI_START="0.12385054795216302" LOG_EFFECT_SIZE="0.4409090820652177" MODIFIED="2009-09-25 22:43:17 +0200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.3724835048061283" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.13874396135265699" WEIGHT="9.614920425470286"/>
<DICH_DATA CI_END="1.4382484413623917" CI_START="0.8847457906195091" EFFECT_SIZE="1.1280444381142287" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="59" LOG_CI_END="0.15783391205051492" LOG_CI_START="-0.05318149494087786" LOG_EFFECT_SIZE="0.052326208554818544" MODIFIED="2009-09-22 16:11:04 +0200" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.12395149460985488" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.015363973016016884" WEIGHT="90.38507957452971"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5457847717600262" CI_END="1.9423338484883337" CI_START="0.9884893644057804" DF="1" EFFECT_SIZE="1.3856321125594868" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="40" I2="35.307940777460054" ID="CMP-001.03.02" LOG_CI_END="0.2883238785561463" LOG_CI_START="-0.005027999091563397" LOG_EFFECT_SIZE="0.14164793973229142" MODIFIED="2009-09-25 22:43:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21375927440587794" P_Z="0.05838751614590939" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="149" WEIGHT="100.0" Z="1.892777115222661">
<NAME>at 2 years</NAME>
<DICH_DATA CI_END="4.639473316197424" CI_START="0.993254506215094" EFFECT_SIZE="2.1466666666666665" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6664686812333315" LOG_CI_START="-0.002939455953032185" LOG_EFFECT_SIZE="0.3317646126401496" MODIFIED="2009-09-25 22:43:36 +0200" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.3932136534069905" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.15461697722567286" WEIGHT="15.580384854127871"/>
<DICH_DATA CI_END="1.8179908253020225" CI_START="0.8528450316293517" EFFECT_SIZE="1.2451764705882353" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" LOG_CI_END="0.25959168717486014" LOG_CI_START="-0.06912987624455645" LOG_EFFECT_SIZE="0.09523090546515184" MODIFIED="2009-09-22 16:11:27 +0200" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.1930926735505473" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.037284780578898225" WEIGHT="84.41961514587213"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.654316748251844E-31" CI_END="2.0580353504534727" CI_START="0.8638227605692278" DF="0" EFFECT_SIZE="1.333333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" I2="100.0" ID="CMP-001.03.03" LOG_CI_END="0.31345283027822257" LOG_CI_START="-0.06357535706162286" LOG_EFFECT_SIZE="0.12493873660829986" MODIFIED="2009-09-13 19:31:06 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.193951909567652" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="104" WEIGHT="100.0" Z="1.2989767462955126">
<NAME>at 35 months</NAME>
<DICH_DATA CI_END="2.0580353504534727" CI_START="0.8638227605692279" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.31345283027822257" LOG_CI_START="-0.0635753570616228" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-09-13 19:31:06 +0200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.22146822356305215" STUDY_ID="STD-Johnson-1995" TOTAL_1="99" TOTAL_2="104" VAR="0.04904817404817405" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="23.271038155709107" CI_END="-0.28100566431648" CI_START="-0.5724067302339824" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4267061972752312" ESTIMABLE="YES" I2="82.81125245364838" I2_Q="7.162223890236003" ID="CMP-001.04" MODIFIED="2009-09-13 19:47:21 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.1177747793378323E-4" P_Q="0.34056574425869346" P_Z="9.464693556888183E-9" Q="2.1542954644188796" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="392" TOTAL_2="396" UNITS="" WEIGHT="300.0" Z="5.740052981661137">
<NAME>Mean number of relapses</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.606302802549411" CI_END="-0.1613143032496332" CI_START="-0.5314049522829813" DF="1" EFFECT_SIZE="-0.34635962776630724" ESTIMABLE="YES" I2="91.38399181020556" ID="CMP-001.04.01" MODIFIED="2009-07-06 15:40:58 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.572933323116814E-4" P_Z="2.4390746201461547E-4" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="143" WEIGHT="100.0" Z="3.668573620510426">
<NAME>within 1 year of follow-up</NAME>
<CONT_DATA CI_END="-0.7752022840279268" CI_START="-2.064797715972073" EFFECT_SIZE="-1.42" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="1.78" ORDER="12" SD_1="0.57" SD_2="1.48" SE="0.3289844716832326" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" WEIGHT="8.2358656210519"/>
<CONT_DATA CI_END="-0.05682913245004145" CI_START="-0.44317086754995855" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="0.51" MEAN_2="0.76" ORDER="13" SD_1="0.65" SD_2="0.86" SE="0.0985583761097988" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" WEIGHT="91.7641343789481"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.510439888740816" CI_END="-0.22101094244686587" CI_START="-0.8066066572204533" DF="1" EFFECT_SIZE="-0.5138087998336596" ESTIMABLE="YES" I2="89.48523925603193" ID="CMP-001.04.02" NO="2" P_CHI2="0.002043078353448302" P_Z="5.830213689336961E-4" STUDIES="2" TAU2="0.0" TOTAL_1="149" TOTAL_2="149" WEIGHT="100.0" Z="3.4393924586797344">
<NAME>at 2 years of follow-up</NAME>
<CONT_DATA CI_END="-1.0502405808818744" CI_START="-3.1497594191181255" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="2.7" ORDER="14" SD_1="0.82" SD_2="2.44" SE="0.5356013821674755" STUDY_ID="STD-Bornstein-1987" TOTAL_1="24" TOTAL_2="23" WEIGHT="7.779581385677886"/>
<CONT_DATA CI_END="-0.0751021585753196" CI_START="-0.6848978414246802" EFFECT_SIZE="-0.3799999999999999" ESTIMABLE="YES" MEAN_1="1.29" MEAN_2="1.67" ORDER="15" SD_1="1.15" SD_2="1.31" SE="0.15556298168215107" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" WEIGHT="92.22041861432211"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2396031622821882" CI_START="-1.0403968377178117" DF="0" EFFECT_SIZE="-0.6399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="0.00173127144287817" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="104" WEIGHT="100.0" Z="3.1328343082211947">
<NAME>at 35 months of follow-up</NAME>
<CONT_DATA CI_END="-0.2396031622821882" CI_START="-1.0403968377178117" EFFECT_SIZE="-0.6399999999999999" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.98" ORDER="16" SD_1="1.45" SD_2="1.46" SE="0.20428785471370436" STUDY_ID="STD-Johnson-1995" TOTAL_1="99" TOTAL_2="104" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-06-20 23:12:16 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Glatiramer acetate versus placebo: secondary outcomes</NAME>
<DICH_OUTCOME CHI2="0.37649295914703745" CI_END="0.9136601142660639" CI_START="0.3977747840931713" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6028523489932885" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.03921533375327131" LOG_CI_START="-0.4003627513179026" LOG_EFFECT_SIZE="-0.21978904253558698" METHOD="MH" NO="1" P_CHI2="0.5394864512007604" P_Q="0.0" P_Z="0.017050780687600797" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="244" TOTAL_2="245" WEIGHT="100.0" Z="2.3856108980161816">
<NAME>Number of hospitalisations at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3227604177546355" CI_START="0.37043745293782454" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.12148119062029968" LOG_CI_START="-0.4312851105917861" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1" O_E="0.0" SE="0.32469766156929963" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="125" VAR="0.10542857142857143" WEIGHT="40.100671140939596"/>
<DICH_DATA CI_END="0.933310164155254" CI_START="0.3099131681164399" EFFECT_SIZE="0.5378151260504201" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.029974004489320367" LOG_CI_START="-0.5087599703279668" LOG_EFFECT_SIZE="-0.2693669874086436" ORDER="2" O_E="0.0" SE="0.28124124636237513" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.07909663865546218" WEIGHT="59.899328859060404"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8153246195083022" CI_START="0.5154267573998972" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6482593037214885" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.08866944353985781" LOG_CI_START="-0.2878330396277804" LOG_EFFECT_SIZE="-0.18825124158381912" METHOD="MH" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="2.1126437738927704E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="120" WEIGHT="99.99999999999999" Z="3.7051515517559874">
<NAME>Number of steroid courses at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8153246195083022" CI_START="0.5154267573998972" EFFECT_SIZE="0.6482593037214885" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="84" LOG_CI_END="-0.08866944353985781" LOG_CI_START="-0.2878330396277804" LOG_EFFECT_SIZE="-0.18825124158381912" ORDER="20" O_E="0.0" SE="0.11698968221774635" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.013686585745409275" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-02 12:41:38 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Glatiramer acetate versus placebo: adverse effects</NAME>
<DICH_OUTCOME CHI2="66.82376009843219" CI_END="4.2221583921802655" CI_START="3.227551732980712" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="3.691508449888808" ESTIMABLE="YES" EVENTS_1="1191" EVENTS_2="210" I2="82.04231551423646" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.6255345216195675" LOG_CI_START="0.5088732121059235" LOG_EFFECT_SIZE="0.5672038668627455" METHOD="MH" MODIFIED="2009-06-21 15:37:30 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.2521212955363126E-9" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3227" TOTAL_2="1988" WEIGHT="400.0" Z="19.05857487075123">
<NAME>Localised to the injection site</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.42326592551817" CI_END="13.733552830720619" CI_START="4.98781917939694" DF="2" EFFECT_SIZE="8.276501568315533" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="16" I2="63.12185263515529" ID="CMP-003.01.01" LOG_CI_END="1.1377829025083002" LOG_CI_START="0.69791070085832" LOG_EFFECT_SIZE="0.9178468016833102" MODIFIED="2009-06-21 15:33:15 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06642843553944044" P_Z="2.8524636165452986E-16" STUDIES="3" TAU2="0.0" TOTAL_1="777" TOTAL_2="467" WEIGHT="100.0" Z="8.179406054197724">
<NAME>Itching</NAME>
<DICH_DATA CI_END="7.3923655929386145" CI_START="1.3852128755349329" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.8687834369822954" LOG_CI_START="0.1415165196575164" LOG_EFFECT_SIZE="0.505149978319906" ORDER="21" O_E="0.0" SE="0.42720018726587655" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.1825" WEIGHT="27.841394166990728"/>
<DICH_DATA CI_END="23.498095231349325" CI_START="3.9850233526618877" EFFECT_SIZE="9.6768" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="5" LOG_CI_END="1.371032659546576" LOG_CI_START="0.6004308707515739" LOG_EFFECT_SIZE="0.9857317651490749" ORDER="23" O_E="0.0" SE="0.45265530527855896" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.2048968253968254" WEIGHT="27.730472277879212"/>
<DICH_DATA CI_END="23.73760345197372" CI_START="4.718900308947027" EFFECT_SIZE="10.583732057416269" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="6" LOG_CI_END="1.3754368704685462" LOG_CI_START="0.6738408025746669" LOG_EFFECT_SIZE="1.0246388365216066" MODIFIED="2009-06-21 15:33:15 +0200" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.4121210032374119" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.16984372130941086" WEIGHT="44.42813355513006"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7716828667743719" CI_END="6.033219166366674" CI_START="2.6718558857077377" DF="2" EFFECT_SIZE="4.014958547659182" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="25" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.7805491020468555" LOG_CI_START="0.4268130295034346" LOG_EFFECT_SIZE="0.603681065775145" MODIFIED="2009-06-21 15:32:01 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6798785035250954" P_Z="2.2363681597711886E-11" STUDIES="3" TAU2="0.0" TOTAL_1="777" TOTAL_2="467" WEIGHT="100.0" Z="6.689694599483085">
<NAME>Swelling</NAME>
<DICH_DATA CI_END="13.660468793005043" CI_START="2.2144188796426785" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="1.1354656034979138" LOG_CI_START="0.34525977549057396" LOG_EFFECT_SIZE="0.7403626894942439" ORDER="24" O_E="0.0" SE="0.4641708149534452" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.21545454545454548" WEIGHT="13.991912589044428"/>
<DICH_DATA CI_END="6.454087206456185" CI_START="1.714407724291588" EFFECT_SIZE="3.3264" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="0.8098348292158313" LOG_CI_START="0.23411411475895666" LOG_EFFECT_SIZE="0.521974471987394" ORDER="26" O_E="0.0" SE="0.3381811975354667" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.11436652236652237" WEIGHT="34.84041979343732"/>
<DICH_DATA CI_END="7.5170679401861245" CI_START="2.2120006542125017" EFFECT_SIZE="4.077714948528346" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="11" LOG_CI_END="0.8760484754708647" LOG_CI_START="0.34478525107788555" LOG_EFFECT_SIZE="0.6104168632743752" MODIFIED="2009-06-21 15:32:01 +0200" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.31206664780380955" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.09738559267150693" WEIGHT="51.16766761751825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.296879058533868" CI_END="5.876832342147878" CI_START="3.5754432729679806" DF="2" EFFECT_SIZE="4.5839154294220235" ESTIMABLE="YES" EVENTS_1="447" EVENTS_2="61" I2="91.03013477917878" ID="CMP-003.01.03" LOG_CI_END="0.769143301073657" LOG_CI_START="0.5533298920308065" LOG_EFFECT_SIZE="0.6612365965522318" MODIFIED="2009-06-21 15:32:39 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.4397804492305433E-5" P_Z="3.134231041038157E-33" STUDIES="3" TAU2="0.0" TOTAL_1="777" TOTAL_2="467" WEIGHT="100.0" Z="12.010374334477909">
<NAME>Redness</NAME>
<DICH_DATA CI_END="2.4135295370906245" CI_START="0.932244650592613" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.38265261813999163" LOG_CI_START="-0.030470100028629096" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="27" O_E="0.0" SE="0.24267032964268392" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.058888888888888886" WEIGHT="16.708529425917625"/>
<DICH_DATA CI_END="7.248075741331465" CI_START="2.760419415308786" EFFECT_SIZE="4.473" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="16" LOG_CI_END="0.8602227230062894" LOG_CI_START="0.4409750733390245" LOG_EFFECT_SIZE="0.6505988981726569" ORDER="29" O_E="0.0" SE="0.24626814472388747" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.06064799910574559" WEIGHT="22.189282106132303"/>
<DICH_DATA CI_END="7.6045960249318" CI_START="3.9309824862681984" EFFECT_SIZE="5.467497945966845" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="33" LOG_CI_END="0.8810761481979748" LOG_CI_START="0.5945011089093737" LOG_EFFECT_SIZE="0.7377886285536742" MODIFIED="2009-06-21 15:32:39 +0200" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.16833559664744716" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.028336873098652026" WEIGHT="61.10218846795008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.85252603961313" CI_END="2.9471199767646032" CI_START="2.0486600565004203" DF="3" EFFECT_SIZE="2.4571623833422342" ESTIMABLE="YES" EVENTS_1="410" EVENTS_2="108" I2="61.795733183613855" ID="CMP-003.01.04" LOG_CI_END="0.4693978162660132" LOG_CI_START="0.3114698999169238" LOG_EFFECT_SIZE="0.39043385809146847" MODIFIED="2009-06-21 15:37:30 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.049160015241593524" P_Z="3.2942818848633857E-22" STUDIES="4" TAU2="0.0" TOTAL_1="896" TOTAL_2="587" WEIGHT="100.0" Z="9.69095670853778">
<NAME>Pain</NAME>
<DICH_DATA CI_END="5.150273162676372" CI_START="1.6048906026772207" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="8" LOG_CI_END="0.7118302639726272" LOG_CI_START="0.2054454340786713" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="30" O_E="0.0" SE="0.2974529557250444" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.0884782608695652" WEIGHT="6.342975221315221"/>
<DICH_DATA CI_END="73.51891786769303" CI_START="0.12446626345164327" EFFECT_SIZE="3.025" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8663991060011735" LOG_CI_START="-0.904948348024198" LOG_EFFECT_SIZE="0.48072537898848766" ORDER="32" O_E="0.0" SE="1.627903212885648" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="2.6500688705234157" WEIGHT="0.39479098887854075"/>
<DICH_DATA CI_END="2.2853322498697604" CI_START="1.344732888116424" EFFECT_SIZE="1.7530434782608695" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="46" LOG_CI_END="0.3589493482988796" LOG_CI_START="0.12863602654087244" LOG_EFFECT_SIZE="0.24379268741987598" ORDER="33" O_E="0.0" SE="0.13528718526998287" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.01830262249827467" WEIGHT="36.32680032127741"/>
<DICH_DATA CI_END="3.6882345985152187" CI_START="2.211443659162939" EFFECT_SIZE="2.855927698032961" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="54" LOG_CI_END="0.5668185375443481" LOG_CI_START="0.3446758793482496" LOG_EFFECT_SIZE="0.45574720844629885" MODIFIED="2009-06-21 15:37:30 +0200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.1304876970482808" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.017027039080963913" WEIGHT="56.935433468528835"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.2827315103594" CI_END="1.5045639971214517" CI_START="1.0861099329308181" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2783277756521225" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="180" I2="57.701259294594465" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.17741066532674138" LOG_CI_START="0.03587378551888164" LOG_EFFECT_SIZE="0.10664222542281147" METHOD="MH" MODIFIED="2009-06-21 15:42:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.358432460966789E-4" P_Q="0.0" P_Z="0.0031418780702902097" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2223" TOTAL_2="1582" WEIGHT="1600.0" Z="2.9535047168434945">
<NAME>Systemic adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8828554582184057" CI_END="5.156942849067511" CI_START="2.0734962648103448" DF="2" EFFECT_SIZE="3.2700002653489038" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="20" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.712392318439457" LOG_CI_START="0.3167032573640265" LOG_EFFECT_SIZE="0.5145477879017417" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6431175918058181" P_Z="3.4432794651100987E-7" STUDIES="3" TAU2="0.0" TOTAL_1="269" TOTAL_2="271" WEIGHT="100.00000000000001" Z="5.0974122452170505">
<NAME>Patterned reaction</NAME>
<DICH_DATA CI_END="99.16103229177347" CI_START="0.25211516482038504" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9963410392362373" LOG_CI_START="-0.5984010305641998" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="2.448925438999349"/>
<DICH_DATA CI_END="13.674793053850516" CI_START="1.6764380937775765" EFFECT_SIZE="4.788" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" LOG_CI_END="1.135920762701934" LOG_CI_START="0.22438752076681198" LOG_EFFECT_SIZE="0.680154141734373" ORDER="3" O_E="0.0" SE="0.5354391384750096" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="0.28669507101086045" WEIGHT="19.513350111548597"/>
<DICH_DATA CI_END="4.7279121675315645" CI_START="1.7013130436655595" EFFECT_SIZE="2.8361344537815127" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="16" LOG_CI_END="0.6746693998717838" LOG_CI_START="0.2307842316772421" LOG_EFFECT_SIZE="0.452726815774513" ORDER="4" O_E="0.0" SE="0.2607403450644934" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.06798552754435108" WEIGHT="78.03772444945206"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5438503877193064" CI_START="0.31738826760529903" DF="0" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.18860521119649018" LOG_CI_START="-0.49840913116797664" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.37678749636000763" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.8838309304048204">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="1.5438503877193064" CI_START="0.31738826760529903" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.18860521119649018" LOG_CI_START="-0.49840913116797664" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="38" O_E="0.0" SE="0.40355562548072954" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.16285714285714284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5948258044252217" CI_END="11.06097349929189" CI_START="1.1592165828148353" DF="1" EFFECT_SIZE="3.5807909604519774" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="37.2972272441753" ID="CMP-003.02.03" LOG_CI_END="1.0437933518118032" LOG_CI_START="0.06416458517314699" LOG_EFFECT_SIZE="0.5539789684924751" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.20663806378467053" P_Z="0.0266425820819317" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="151" WEIGHT="100.0" Z="2.216714868762932">
<NAME>Palpitations</NAME>
<DICH_DATA CI_END="7.123142687698108" CI_START="0.5615498910204517" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8526716440299906" LOG_CI_START="-0.2506116527020283" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="40" O_E="0.0" SE="0.6480740698407861" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.42000000000000004" WEIGHT="85.76271186440678"/>
<DICH_DATA CI_END="230.1470439113463" CI_START="0.7460151638854723" EFFECT_SIZE="13.103174603174603" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.362005401036488" LOG_CI_START="-0.12725234474602648" LOG_EFFECT_SIZE="1.1173765281452308" ORDER="42" O_E="0.0" SE="1.4622023218972175" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="2.1380356301616144" WEIGHT="14.237288135593221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03527631357653528" CI_END="1.1351816537733077" CI_START="0.6782253724436689" DF="1" EFFECT_SIZE="0.8774445851001769" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="74" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.055065363660305074" LOG_CI_START="-0.1686259672766549" LOG_EFFECT_SIZE="-0.056780301808174935" MODIFIED="2009-06-21 15:42:37 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8510178998652629" P_Z="0.3197323229072072" STUDIES="2" TAU2="0.0" TOTAL_1="652" TOTAL_2="339" WEIGHT="99.99999999999999" Z="0.9950081311528347">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.7586721624815742" CI_START="0.38026444501373474" EFFECT_SIZE="0.8177777777777778" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.24518488931825047" LOG_CI_START="-0.41991427952190247" LOG_EFFECT_SIZE="-0.087364695101826" ORDER="43" O_E="0.0" SE="0.39068254407068903" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.15263285024154588" WEIGHT="9.784796729408345"/>
<DICH_DATA CI_END="1.1613438008792147" CI_START="0.6727617117463781" EFFECT_SIZE="0.8839160839160839" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="65" LOG_CI_END="0.06496080606222729" LOG_CI_START="-0.17213873309961855" LOG_EFFECT_SIZE="-0.05358896351869561" MODIFIED="2009-06-21 15:42:37 +0200" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.13927344296531566" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.019397091915413035" WEIGHT="90.21520327059164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="34.06796254835959" CI_START="1.8785978148576319" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" I2="0.0" ID="CMP-003.02.05" LOG_CI_END="1.532346161144525" LOG_CI_START="0.2738338128393619" LOG_EFFECT_SIZE="0.9030899869919435" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.0049099547996075835" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="125" WEIGHT="100.0" Z="2.812882768590462">
<NAME>Dyspnea</NAME>
<DICH_DATA CI_END="34.06796254835959" CI_START="1.8785978148576319" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.532346161144525" LOG_CI_START="0.2738338128393619" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="46" O_E="0.0" SE="0.7392563831310488" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="125" VAR="0.5465" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.9881862656605485" CI_START="0.14309864705723846" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.02.06" LOG_CI_END="0.844364472308381" LOG_CI_START="-0.844364472308381" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="125" WEIGHT="100.0" Z="0.0">
<NAME>Anxiety</NAME>
<DICH_DATA CI_END="6.9881862656605485" CI_START="0.14309864705723846" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.844364472308381" LOG_CI_START="-0.844364472308381" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.9919677414109795" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="125" VAR="0.984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.708841356172185" CI_START="0.4118368271994768" DF="0" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.02.07" LOG_CI_END="0.7565479745014614" LOG_CI_START="-0.3852748205776382" LOG_EFFECT_SIZE="0.18563657696191166" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5239303999149231" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.6372985486481548">
<NAME>Faintness</NAME>
<DICH_DATA CI_END="5.7088413561721865" CI_START="0.41183682719947673" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7565479745014615" LOG_CI_START="-0.38527482057763823" LOG_EFFECT_SIZE="0.18563657696191166" ORDER="49" O_E="0.0" SE="0.670712361943455" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.4498550724637681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.175591273092662" CI_START="0.27016921103118596" DF="0" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-003.02.08" LOG_CI_END="0.3375773080695435" LOG_CI_START="-0.5683641454736825" LOG_EFFECT_SIZE="-0.11539341870206953" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.6175701394223578" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.4992970435880727">
<NAME>Drowsiness</NAME>
<DICH_DATA CI_END="2.175591273092662" CI_START="0.27016921103118596" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3375773080695435" LOG_CI_START="-0.5683641454736825" LOG_EFFECT_SIZE="-0.11539341870206953" ORDER="51" O_E="0.0" SE="0.5321544942938108" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.2831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9043462122338104" CI_START="0.12375864424817068" DF="0" EFFECT_SIZE="0.33454545454545453" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-003.02.09" LOG_CI_END="-0.043665276075372246" LOG_CI_START="-0.9074244568940425" LOG_EFFECT_SIZE="-0.4755448664847074" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.030917993885266275" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.1581265520316397">
<NAME>Rash</NAME>
<DICH_DATA CI_END="0.9043462122338104" CI_START="0.12375864424817068" EFFECT_SIZE="0.33454545454545453" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.043665276075372246" LOG_CI_START="-0.9074244568940425" LOG_EFFECT_SIZE="-0.4755448664847074" ORDER="53" O_E="0.0" SE="0.5073764184897892" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.2574308300395257" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.533035597908136" CI_START="0.25280645169509575" DF="0" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.02.10" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.7099331091968111" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.37194592843457325">
<NAME>Cramps</NAME>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="55" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.058938471708105" CI_START="0.5075131122000223" DF="0" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-003.02.11" LOG_CI_END="0.3136433685719355" LOG_CI_START="-0.29455273275947486" LOG_EFFECT_SIZE="0.009545317906230361" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.9509441251410033" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.06152120763760834">
<NAME>Joint pain</NAME>
<DICH_DATA CI_END="2.058938471708105" CI_START="0.5075131122000223" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3136433685719355" LOG_CI_START="-0.29455273275947486" LOG_EFFECT_SIZE="0.009545317906230361" ORDER="57" O_E="0.0" SE="0.35725740054132665" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.1276328502415459" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.175591273092662" CI_START="0.27016921103118596" DF="0" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-003.02.12" LOG_CI_END="0.3375773080695435" LOG_CI_START="-0.5683641454736825" LOG_EFFECT_SIZE="-0.11539341870206953" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.6175701394223578" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.4992970435880727">
<NAME>Appetite loss</NAME>
<DICH_DATA CI_END="2.175591273092662" CI_START="0.27016921103118596" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3375773080695435" LOG_CI_START="-0.5683641454736825" LOG_EFFECT_SIZE="-0.11539341870206953" ORDER="59" O_E="0.0" SE="0.5321544942938108" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.2831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.874146434896417" CI_START="0.6009947571922385" DF="0" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-003.02.13" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.49361949744298717" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.6845633627749433">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="2.874146434896417" CI_START="0.6009947571922385" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" ORDER="61" O_E="0.0" SE="0.3992228475270142" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.15937888198757763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9058209348876407" CI_END="2.197568740347136" CI_START="0.7847335718212184" DF="1" EFFECT_SIZE="1.313204465014974" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="20" I2="47.52917329775497" ID="CMP-003.02.14" LOG_CI_END="0.3419424687681204" LOG_CI_START="-0.10527776736678354" LOG_EFFECT_SIZE="0.11833235070066843" MODIFIED="2009-06-21 15:39:31 +0200" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.16742845228684355" P_Z="0.29964531691066265" STUDIES="2" TAU2="0.0" TOTAL_1="652" TOTAL_2="339" WEIGHT="100.0" Z="1.037194325479102">
<NAME>Abdominal discomfort</NAME>
<DICH_DATA CI_END="2.6695154555464082" CI_START="0.8563457632430455" EFFECT_SIZE="1.5119617224880382" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="15" LOG_CI_END="0.4264324396120168" LOG_CI_START="-0.06735084659731731" LOG_EFFECT_SIZE="0.17954079650734978" MODIFIED="2009-06-21 15:39:31 +0200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.29005074658605023" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.08412943559512513" WEIGHT="79.29529346670999"/>
<DICH_DATA CI_END="2.0551828882219874" CI_START="0.14826125779181165" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" ORDER="63" O_E="0.0" SE="0.670712361943455" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.4498550724637681" WEIGHT="20.704706533290008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.277733056601674" CI_START="0.4451890697249111" DF="0" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-003.02.15" LOG_CI_END="0.6312136798002469" LOG_CI_START="-0.3514555069977739" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Z="0.576853742289344" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.5579862993977052">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="4.277733056601674" CI_START="0.4451890697249111" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6312136798002469" LOG_CI_START="-0.3514555069977739" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="65" O_E="0.0" SE="0.5772247446160823" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="0.3331884057971014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.873257535648168" CI_START="0.061009463554260755" DF="0" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.02.16" LOG_CI_END="1.1421784483587567" LOG_CI_START="-1.214602793667646" LOG_EFFECT_SIZE="-0.036212172654444715" MODIFIED="2009-06-13 22:42:36 +0200" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Z="0.9519723936651197" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.060230073915246075">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="13.873257535648168" CI_START="0.061009463554260755" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1421784483587567" LOG_CI_START="-1.214602793667646" LOG_EFFECT_SIZE="-0.036212172654444715" ORDER="67" O_E="0.0" SE="1.384384967821608" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="1.9165217391304348" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.365566637791002" CI_END="2.2273646064686985" CI_START="0.9369817229223114" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.44464525975937" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="26" I2="25.45055778774568" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.3477913143023425" LOG_CI_START="-0.028268880522469373" LOG_EFFECT_SIZE="0.15976121688993658" METHOD="MH" MODIFIED="2009-11-02 12:41:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2518015887400278" P_Q="0.0" P_Z="0.09585322607975391" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1992" TOTAL_2="1133" WEIGHT="100.0" Z="1.6652984577452459">
<NAME>Adverse effects causing treatment withdrawal</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="91.34475988701922" CI_START="0.23320193927135308" EFFECT_SIZE="4.615384615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9606836385257036" LOG_CI_START="-0.6322678423720901" LOG_EFFECT_SIZE="0.6642078980768068" ORDER="69" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Bornstein-1987" TOTAL_1="25" TOTAL_2="23" VAR="2.319871794871795" WEIGHT="1.5242909318789364"/>
<DICH_DATA CI_END="8.890375199741175" CI_START="0.25735404431539344" EFFECT_SIZE="1.5126050420168067" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9489200898497112" LOG_CI_START="-0.5894690024281607" LOG_EFFECT_SIZE="0.1797255437107753" ORDER="70" O_E="0.0" SE="0.9036573679528442" STUDY_ID="STD-Comi-2001" TOTAL_1="119" TOTAL_2="120" VAR="0.8165966386554622" WEIGHT="5.838127482896473"/>
<DICH_DATA CI_END="1.5430837769475503" CI_START="0.16201323851290647" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.18838950537509858" LOG_CI_START="-0.7904494967030609" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-07-13 16:44:13 +0200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.5749748751519157" STUDY_ID="STD-Filippi-2006" TOTAL_1="1096" TOTAL_2="548" VAR="0.33059610705596104" WEIGHT="23.450629721214405"/>
<DICH_DATA CI_END="42.52680786360582" CI_START="0.5973079400050274" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.628662785035908" LOG_CI_START="-0.22380171214485756" LOG_EFFECT_SIZE="0.7024305364455253" ORDER="71" O_E="0.0" SE="1.0881468154911322" STUDY_ID="STD-Johnson-1995" TOTAL_1="125" TOTAL_2="126" VAR="1.184063492063492" WEIGHT="2.9196501146930287"/>
<DICH_DATA CI_END="2.6207158458286317" CI_START="0.9068344148503646" EFFECT_SIZE="1.5416080307721174" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="17" LOG_CI_END="0.41841993461365695" LOG_CI_START="-0.04247200652523178" LOG_EFFECT_SIZE="0.1879739640442126" MODIFIED="2009-06-21 15:43:24 +0200" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.27073020767688666" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="627" TOTAL_2="316" VAR="0.07329484534877018" WEIGHT="66.26730174931717"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-03-05 16:23:49 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Glatiramer acetate versus placebo in progressive patients</NAME>
<DICH_OUTCOME CHI2="0.5830540797450778" CI_END="1.071382314875108" CI_START="0.666623951923669" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8451089354415637" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="158" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.02994447327116689" LOG_CI_START="-0.17611908611292967" LOG_EFFECT_SIZE="-0.07308730642088142" METHOD="MH" MODIFIED="2010-03-05 16:23:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9003005638250624" P_Q="0.0" P_Z="0.16442776684366794" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1018" TOTAL_2="530" WEIGHT="300.0" Z="1.3903330481151164">
<NAME>progression of disability</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2738765803700154" CI_START="0.6037547751192285" DF="0" EFFECT_SIZE="0.8769886363636363" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="55" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.10512735338338222" LOG_CI_START="-0.2191394213754535" LOG_EFFECT_SIZE="-0.05700603399603567" MODIFIED="2010-03-05 16:23:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49074615447328207" STUDIES="1" TAU2="0.0" TOTAL_1="482" TOTAL_2="244" WEIGHT="100.0" Z="0.6891225511265638">
<NAME>at 1 year</NAME>
<DICH_DATA CI_END="1.2738765803700152" CI_START="0.6037547751192285" EFFECT_SIZE="0.8769886363636363" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="55" LOG_CI_END="0.10512735338338214" LOG_CI_START="-0.2191394213754535" LOG_EFFECT_SIZE="-0.05700603399603567" MODIFIED="2010-03-05 16:23:49 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.1904759086397626" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="482" TOTAL_2="244" VAR="0.036281071772143195" WEIGHT="100.0">
<FOOTNOTE>data were obatined from survival curve fig.2</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.438822673162678" CI_END="1.1891525000093364" CI_START="0.5975838234845866" DF="1" EFFECT_SIZE="0.8429817896383255" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="80" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.07523755324410396" LOG_CI_START="-0.22360116732797816" LOG_EFFECT_SIZE="-0.07418180704193712" MODIFIED="2010-03-05 16:23:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5076912719980091" P_Z="0.33052460140101836" STUDIES="2" TAU2="0.0" TOTAL_1="422" TOTAL_2="240" WEIGHT="99.99999999999999" Z="0.9730577739856608">
<NAME>at 2 years</NAME>
<DICH_DATA CI_END="1.6088911020044034" CI_START="0.2447774636360995" EFFECT_SIZE="0.6275510204081632" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.2065266498174353" LOG_CI_START="-0.6112285696515916" LOG_EFFECT_SIZE="-0.20235095991707813" MODIFIED="2009-06-23 19:20:10 +0200" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.48035346386972727" STUDY_ID="STD-Bornstein-1991" TOTAL_1="51" TOTAL_2="55" VAR="0.23073945025164536" WEIGHT="15.801775988771018"/>
<DICH_DATA CI_END="1.2798104236891836" CI_START="0.6097915132684402" EFFECT_SIZE="0.8834124376293051" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="66" LOG_CI_END="0.10714564305158943" LOG_CI_START="-0.2148186241922415" LOG_EFFECT_SIZE="-0.05383649057032602" MODIFIED="2010-03-05 16:23:07 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.1891234043278528" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="371" TOTAL_2="185" VAR="0.03576766206455649" WEIGHT="84.19822401122897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4979808424886152" CI_START="0.379366683171022" DF="0" EFFECT_SIZE="0.7538461538461538" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.17550625925484753" LOG_CI_START="-0.4209408124835313" LOG_EFFECT_SIZE="-0.12271727661434192" MODIFIED="2010-03-05 16:23:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4199465740829518" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="46" WEIGHT="100.0" Z="0.80651395183796">
<NAME>at 3 years</NAME>
<DICH_DATA CI_END="1.4979808424886154" CI_START="0.3793666831710219" EFFECT_SIZE="0.7538461538461538" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" LOG_CI_END="0.1755062592548476" LOG_CI_START="-0.42094081248353143" LOG_EFFECT_SIZE="-0.12271727661434192" MODIFIED="2010-03-05 16:23:21 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.3503559623997456" STUDY_ID="STD-Wolinsky-2007" TOTAL_1="114" TOTAL_2="46" VAR="0.12274930038905194" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-04-14 11:33:11 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-09-26 20:08:10 +0200" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Glatiramer acetate versus placebo in relapsing remitting patient, outcome: 1.1 Patients who progressed.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-11-02 12:54:35 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Glatiramer acetate versus placebo in relapsing remitting patient, outcome: 1.2 Change in disability score at the end of follow-up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-09-25 22:43:38 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Glatiramer acetate versus placebo in relapsing remitting patient, outcome: 1.3 Patients relapse free.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-09-13 19:48:44 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Glatiramer acetate versus placebo in relapsing remitting patient, outcome: 1.4 Mean number of relapses.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-09-13 19:50:12 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Glatiramer acetate versus placebo: secondary outcomes, outcome: 2.1 Number of hospitalisations at the end of follow-up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-09-13 19:50:30 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Glatiramer acetate versus placebo: secondary outcomes, outcome: 2.2 Number of steroid courses at the end of follow-up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-09-13 19:50:30 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-003.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Glatiramer acetate versus placebo: adverse effects, outcome: 3.1 Localised to the injection site.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-03-05 16:23:50 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-004.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 glatiramer acetate versus placebo in progressive patients, outcome: 4.1 progression of disability.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-04-14 11:33:11 +0200" MODIFIED_BY="[Empty name]" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-04-14 11:33:11 +0200" MODIFIED_BY="[Empty name]" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Therapy with glatiramer acetate for MS</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>From Dr. Douglas L. A. (November, 2004)</P>
<P>I believe that the review of Copaxone therapy by Munari et al., may have been excessively negative and could benefit from revision and updating, taking into account, in particular, the report of Boneschi et al. (2003), which was published shortly after the cut-off date for the original review and included more complete data from the relevant clinical trials. </P>
<P>I am a physician involved with clinical research in MS and have received financial support for research, consultancy and educational activities from multiple pharmaceutical companies, including TEVA. </P>
<P>(Dr. Munari may wish to consider revising his conflict of interest declaration, as well, not only to reflect recent pharmaceutical industry sponsored activities, but also to declare a potential bias due to his job as a hospital administrator.)</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Author's reply (February, 2005)</P>
<P>The Cochrane review has been updated taking into account the re-analysis of RRMS glatiramer trials published by Boneschi et al., as Dr. Arnold suggested.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Dr. Douglas L. Arnold, Canada.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2009-11-02 19:56:10 +0100" MODIFIED_BY="Deirdre M Beecher">
<APPENDIX ID="APP-01" MODIFIED="2009-11-02 19:54:50 +0100" MODIFIED_BY="Deirdre M Beecher" NO="1">
<TITLE MODIFIED="2009-11-02 19:54:50 +0100" MODIFIED_BY="Deirdre M Beecher">CENTRAL (Issue 1, 2009)</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-22 19:18:13 +0200" MODIFIED_BY="[Empty name]">
<P>#1MeSH descriptor Multiple Sclerosis explode all trees<BR/>#2MeSH descriptor Demyelinating Diseases, this term only<BR/>#3MeSH descriptor Myelitis, Transverse, this term only<BR/>#4MeSH descriptor Optic Neuritis explode all trees<BR/>#5MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only<BR/>#6(multiple sclerosis)<BR/>#7(demyelinating disease*)<BR/>#8(transverse myelitis)<BR/>#9(neuromyelitis optica)<BR/>#10(optic neuritis)<BR/>#11(encephalomyelitis acute disseminated)<BR/>#12(devic)<BR/>#13(#1 OR #1 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)<BR/>#14(copolymer-1 )<BR/>#15cpx OR cop-1 OR cop1 OR copolymer<BR/>#16(copaxone)<BR/>#17(glatiramer NEXT acetate)<BR/>#18(glatiramer)<BR/>#19(#14 OR #15 OR #16 OR #17 OR #18)<BR/>#20(#19 AND #13)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-11-02 19:55:36 +0100" MODIFIED_BY="Deirdre M Beecher" NO="2">
<TITLE MODIFIED="2009-11-02 19:55:36 +0100" MODIFIED_BY="Deirdre M Beecher">MEDLINE (PubMed) (January 1966 - 26 March 2009)</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-22 19:23:13 +0200" MODIFIED_BY="[Empty name]">
<P>(((("Multiple Sclerosis"[mh]) OR ("Myelitis, Transverse"[mh:noexp]) OR ("Demyelinating Diseases"[mh:noexp]) OR ("Encephalomyelitis, Acute Disseminated"[mh:noexp]) OR ("Optic Neuritis"[mh])) OR ((("multiple sclerosis") OR ("neuromyelitis optica") OR ("transverse myelitis") OR (encephalomyelitis) OR (devic) OR ("optic neuritis")) OR ("demyelinating disease*") OR ("acute disseminated encephalomyelitis"))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh]) NOT ((animals[mh]) AND (human[mh]))))) AND (copolymer-1 OR cop-1 OR copaxone OR "glatiramer acetate" OR glatiramer)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-11-02 19:56:10 +0100" MODIFIED_BY="Deirdre M Beecher" NO="3">
<TITLE MODIFIED="2009-11-02 19:56:10 +0100" MODIFIED_BY="Deirdre M Beecher">EMBASE (EMBASE.com) (1974- 26 March 2009)</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-22 19:24:33 +0200" MODIFIED_BY="[Empty name]">
<P>((('encephalomyelitis'/exp) OR ('demyelinating disease'/exp) OR ('multiple sclerosis'/exp) OR ('myelooptic neuropathy'/exp) OR ('multiple sclerosis':ti,ab) OR ('neuromyelitis optica':ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ti,ab)) AND (('crossover procedure'/exp) OR ('double blind procedure'/exp) OR ('single blind procedure'/exp) OR ('randomized controlled trial'/exp) OR (random*:ab,ti) OR (factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR ('controlled clinical trial'/exp) OR (placebo:ab,ti) OR ('double blind':ab,ti) OR ('single blind':ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti)) AND ('copolymer 1':ab,ti OR 'cop-1':ab,ti OR copaxone:ab,ti OR 'glatiramer acetate':ab,ti OR cpx:ab,ti OR copolymer:ab,ti OR cop1:ab,ti)) AND [humans]/lim AND [embase]/lim</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-10-18 15:11:32 +0200" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>